|
G |
Akt1 |
AKT serine/threonine kinase 1 |
decreases phosphorylation |
ISO |
Ku 0063794 results in decreased phosphorylation of AKT1 protein |
CTD |
PMID:22885370 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Eif4ebp1 |
eukaryotic translation initiation factor 4E binding protein 1 |
multiple interactions |
ISO |
[Ku 0063794 co-treated with 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine] results in decreased phosphorylation of EIF4EBP1 protein; [Ku 0063794 co-treated with AZD 6244] results in decreased phosphorylation of EIF4EBP1 protein; [Ku 0063794 co-treated with mirdametinib] results in decreased phosphorylation of EIF4EBP1 protein; Ku 0063794 inhibits the reaction [dactolisib results in decreased phosphorylation of EIF4EBP1 protein] |
CTD |
PMID:22415236 |
|
NCBI chr16:64,792,595...64,805,984
Ensembl chr16:64,790,226...64,805,984
|
|
G |
Rps6 |
ribosomal protein S6 |
multiple interactions decreases phosphorylation |
ISO |
[Ku 0063794 co-treated with 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine] results in decreased phosphorylation of RPS6 protein Ku 0063794 results in decreased phosphorylation of RPS6 protein |
CTD |
PMID:22415236 PMID:22885370 |
|
NCBI chr 5:101,371,716...101,374,576
Ensembl chr 5:101,371,136...101,374,602 Ensembl chr 5:101,371,136...101,374,602
|
|
|
G |
Abca1 |
ATP binding cassette subfamily A member 1 |
increases expression |
ISO |
palbociclib results in increased expression of ABCA1 mRNA |
CTD |
PMID:22869556 |
|
NCBI chr 5:67,678,267...67,801,162
Ensembl chr 5:67,681,297...67,801,170
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions increases phosphorylation |
ISO |
BMS 754807 inhibits the reaction [palbociclib results in increased phosphorylation of AKT1 protein]; palbociclib promotes the reaction [idelalisib results in decreased phosphorylation of AKT1 protein] |
CTD |
PMID:23676220 PMID:24986516 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Anln |
anillin, actin binding protein |
decreases expression |
ISO |
palbociclib results in decreased expression of ANLN mRNA |
CTD |
PMID:22869556 |
|
NCBI chr 8:20,858,227...20,921,602
Ensembl chr 8:20,858,228...20,921,538
|
|
G |
Apoe |
apolipoprotein E |
increases expression |
ISO |
palbociclib results in increased expression of APOE mRNA |
CTD |
PMID:28620137 |
|
NCBI chr 1:79,353,924...79,357,852
Ensembl chr 1:79,353,916...79,357,932
|
|
G |
Asf1b |
anti-silencing function 1B histone chaperone |
decreases expression |
ISO |
palbociclib results in decreased expression of ASF1B mRNA |
CTD |
PMID:22869556 |
|
NCBI chr19:24,181,024...24,195,604
Ensembl chr19:24,181,028...24,195,549
|
|
G |
Aurka |
aurora kinase A |
decreases expression |
ISO |
palbociclib results in decreased expression of AURKA mRNA |
CTD |
PMID:22869556 |
|
NCBI chr 3:161,128,309...161,144,524
Ensembl chr 3:161,128,313...161,144,390
|
|
G |
Aurkb |
aurora kinase B |
decreases expression |
ISO |
palbociclib results in decreased expression of AURKB mRNA |
CTD |
PMID:22869556 |
|
NCBI chr10:53,744,290...53,750,831
Ensembl chr10:53,745,142...53,750,837
|
|
G |
Bard1 |
BRCA1 associated RING domain 1 |
decreases expression |
ISO |
palbociclib results in decreased expression of BARD1 mRNA |
CTD |
PMID:22869556 PMID:28620137 |
|
NCBI chr 9:72,616,070...72,694,553
Ensembl chr 9:72,623,155...72,694,265
|
|
G |
Birc5 |
baculoviral IAP repeat-containing 5 |
decreases expression |
ISO |
palbociclib results in decreased expression of BIRC5 mRNA |
CTD |
PMID:22869556 |
|
NCBI chr10:103,072,530...103,081,382
Ensembl chr10:103,073,408...103,081,380
|
|
G |
Bora |
bora, aurora kinase A activator |
decreases expression |
ISO |
palbociclib results in decreased expression of BORA mRNA |
CTD |
PMID:22869556 |
|
NCBI chr15:75,797,624...75,835,599
Ensembl chr15:75,797,891...75,821,322
|
|
G |
Bub1 |
BUB1 mitotic checkpoint serine/threonine kinase |
decreases expression |
ISO |
palbociclib results in decreased expression of BUB1 mRNA |
CTD |
PMID:22869556 |
|
NCBI chr 3:115,020,254...115,051,650
Ensembl chr 3:115,020,254...115,051,650
|
|
G |
Casp3 |
caspase 3 |
multiple interactions increases cleavage decreases cleavage |
ISO |
[palbociclib results in increased susceptibility to idelalisib] which results in increased cleavage of CASP3 protein; palbociclib inhibits the reaction [Camptothecin results in increased activity of CASP3 protein]; palbociclib inhibits the reaction [Carboplatin results in increased activity of CASP3 protein]; palbociclib inhibits the reaction [Doxorubicin results in increased activity of CASP3 protein]; palbociclib inhibits the reaction [Doxorubicin results in increased cleavage of CASP3 protein]; palbociclib inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; palbociclib inhibits the reaction [Paclitaxel results in increased activity of CASP3 protein] palbociclib results in increased cleavage of CASP3 protein [CDKN2A gene mutant form results in increased susceptibility to palbociclib] which affects the activity of CASP3 protein palbociclib results in decreased cleavage of CASP3 protein |
CTD |
PMID:22302033 PMID:22751436 PMID:23676220 PMID:24098593 PMID:27099147 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp7 |
caspase 7 |
multiple interactions |
ISO |
palbociclib inhibits the reaction [Camptothecin results in increased activity of CASP7 protein]; palbociclib inhibits the reaction [Carboplatin results in increased activity of CASP7 protein]; palbociclib inhibits the reaction [Doxorubicin results in increased activity of CASP7 protein]; palbociclib inhibits the reaction [Etoposide results in increased activity of CASP7 protein]; palbociclib inhibits the reaction [Paclitaxel results in increased activity of CASP7 protein] [CDKN2A gene mutant form results in increased susceptibility to palbociclib] which affects the activity of CASP7 protein |
CTD |
PMID:22302033 PMID:24098593 |
|
NCBI chr 1:255,437,195...255,476,737
Ensembl chr 1:255,437,172...255,476,729
|
|
G |
Ccn1 |
cellular communication network factor 1 |
increases expression |
ISO |
palbociclib results in increased expression of CCN1 mRNA |
CTD |
PMID:22869556 |
|
NCBI chr 2:234,562,410...234,565,370
Ensembl chr 2:234,562,408...234,565,484
|
|
G |
Ccna2 |
cyclin A2 |
decreases expression multiple interactions |
ISO |
palbociclib results in decreased expression of CCNA2 mRNA; palbociclib results in decreased expression of CCNA2 protein E2F2 protein inhibits the reaction [palbociclib results in decreased expression of CCNA2 protein]; palbociclib inhibits the reaction [Doxorubicin results in increased expression of CCNA2 protein]; palbociclib inhibits the reaction [RBL1 protein binds to CCNA2 promoter]; palbociclib promotes the reaction [RB1 protein binds to CCNA2 promoter]; RB1 protein affects the reaction [palbociclib inhibits the reaction [Doxorubicin results in increased expression of CCNA2 protein]]; RB1 protein affects the reaction [palbociclib inhibits the reaction [RBL1 protein binds to CCNA2 promoter]]; RB1 protein affects the reaction [palbociclib results in decreased expression of CCNA2 protein] |
CTD |
PMID:20100483 PMID:20473330 PMID:21367843 PMID:21593195 PMID:22751436 PMID:22869556 PMID:23708653 PMID:24606660 PMID:26318986 More...
|
|
NCBI chr 2:119,427,239...119,433,645
Ensembl chr 2:119,426,089...119,433,577
|
|
G |
Ccnb1 |
cyclin B1 |
decreases expression |
ISO |
palbociclib results in decreased expression of CCNB1 mRNA |
CTD |
PMID:22869556 |
|
NCBI chr 2:31,912,190...31,921,163
Ensembl chr 2:31,912,193...31,921,172
|
|
G |
Ccnb2 |
cyclin B2 |
decreases expression |
ISO |
palbociclib results in decreased expression of CCNB2 mRNA |
CTD |
PMID:22869556 PMID:28620137 |
|
NCBI chr 8:71,087,594...71,100,794
Ensembl chr 8:71,087,595...71,100,874
|
|
G |
Ccnd1 |
cyclin D1 |
decreases response to substance multiple interactions increases expression |
ISO |
CCND1 gene results in decreased susceptibility to palbociclib [CDKN2A gene mutant form results in increased expression of CCND1 protein] which results in increased susceptibility to palbociclib palbociclib results in increased expression of CCND1 protein [BMS 754807 co-treated with palbociclib] results in increased expression of CCND1 protein; Doxorubicin inhibits the reaction [palbociclib results in increased expression of CCND1 protein]; palbociclib inhibits the reaction [[CDK4 protein binds to CCND1 protein] which results in increased phosphorylation of SHOX2 protein]; palbociclib promotes the reaction [CCND1 protein binds to CDKN1B protein binds to CDK4 protein]; palbociclib promotes the reaction [CDK4 protein binds to CCND1 protein] |
CTD |
PMID:20473330 PMID:21278246 PMID:22094256 PMID:22751436 PMID:22869556 PMID:23708653 PMID:24098593 PMID:24986516 More...
|
|
NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602
|
|
G |
Ccnd2 |
cyclin D2 |
multiple interactions |
ISO |
[CDKN2A gene mutant form results in increased expression of CCND2 protein] which results in increased susceptibility to palbociclib |
CTD |
PMID:24098593 |
|
NCBI chr 4:159,966,883...159,989,261
Ensembl chr 4:159,962,363...159,989,495
|
|
G |
Ccnd3 |
cyclin D3 |
multiple interactions increases expression |
ISO |
palbociclib inhibits the reaction [[CDK6 protein binds to CCND3 protein] which results in increased phosphorylation of MEF2D protein]; palbociclib inhibits the reaction [[CDK6 protein binds to CCND3 protein] which results in increased phosphorylation of RB1 protein]; palbociclib inhibits the reaction [[CDK6 protein binds to CCND3 protein] which results in increased phosphorylation of RBL2 protein]; palbociclib inhibits the reaction [[CDK6 protein binds to CCND3 protein] which results in increased phosphorylation of SENP3 protein]; palbociclib inhibits the reaction [[CDK6 protein binds to CCND3 protein] which results in increased phosphorylation of ZEB1 protein] [CDKN2A gene mutant form results in increased expression of CCND3 protein] which results in increased susceptibility to palbociclib palbociclib results in increased expression of CCND3 protein |
CTD |
PMID:20473330 PMID:22094256 PMID:24098593 |
|
NCBI chr 9:13,394,161...13,400,341
Ensembl chr 9:13,394,169...13,489,371
|
|
G |
Ccne1 |
cyclin E1 |
decreases response to substance decreases expression increases expression |
ISO |
CCNE1 protein results in decreased susceptibility to palbociclib palbociclib results in decreased expression of CCNE1 protein palbociclib results in increased expression of CCNE1 protein |
CTD |
PMID:17537993 PMID:21278246 PMID:21880723 PMID:23708653 |
|
NCBI chr 1:90,781,947...90,791,188
Ensembl chr 1:90,781,949...90,791,101
|
|
G |
Ccne2 |
cyclin E2 |
decreases expression |
ISO |
palbociclib analog results in decreased expression of CCNE2 mRNA; palbociclib results in decreased expression of CCNE2 mRNA |
CTD |
PMID:15542782 PMID:22869556 PMID:26318986 |
|
NCBI chr 5:24,285,078...24,298,258
Ensembl chr 5:24,284,922...24,297,632
|
|
G |
Ccnf |
cyclin F |
decreases expression |
ISO |
palbociclib results in decreased expression of CCNF mRNA |
CTD |
PMID:22869556 PMID:24606660 |
|
NCBI chr10:13,253,073...13,279,140
Ensembl chr10:13,253,380...13,279,101
|
|
G |
Cdc20 |
cell division cycle 20 |
decreases expression |
ISO |
palbociclib results in decreased expression of CDC20 mRNA |
CTD |
PMID:22869556 |
|
NCBI chr 5:131,966,203...131,970,406
Ensembl chr 5:131,966,215...131,970,512
|
|
G |
Cdc25a |
cell division cycle 25A |
decreases expression |
ISO |
palbociclib results in decreased expression of CDC25A mRNA |
CTD |
PMID:22869556 |
|
NCBI chr 8:109,864,356...109,882,734
Ensembl chr 8:109,864,478...109,882,701
|
|
G |
Cdc25c |
cell division cycle 25C |
decreases expression |
ISO |
palbociclib results in decreased expression of CDC25C mRNA |
CTD |
PMID:22869556 |
|
NCBI chr18:26,335,156...26,356,199
Ensembl chr18:26,335,834...26,356,185
|
|
G |
Cdc37 |
cell division cycle 37, HSP90 cochaperone |
multiple interactions |
ISO |
palbociclib inhibits the reaction [CDC37 protein binds to CDK4 protein]; palbociclib inhibits the reaction [CDC37 protein binds to CDK6 protein] |
CTD |
PMID:29091774 |
|
NCBI chr 8:19,677,400...19,690,761
Ensembl chr 8:19,671,938...19,690,809
|
|
G |
Cdc45 |
cell division cycle 45 |
decreases expression |
ISO |
palbociclib results in decreased expression of CDC45 mRNA |
CTD |
PMID:22869556 |
|
NCBI chr11:82,185,427...82,210,630
Ensembl chr11:82,185,473...82,210,619
|
|
G |
Cdca3 |
cell division cycle associated 3 |
decreases expression |
ISO |
palbociclib results in decreased expression of CDCA3 mRNA |
CTD |
PMID:22869556 |
|
NCBI chr 4:157,634,775...157,638,799
Ensembl chr 4:157,634,928...157,638,799
|
|
G |
Cdca5 |
cell division cycle associated 5 |
decreases expression |
ISO |
palbociclib results in decreased expression of CDCA5 mRNA |
CTD |
PMID:22869556 |
|
NCBI chr 1:203,378,550...203,392,027
Ensembl chr 1:203,378,577...203,392,023
|
|
G |
Cdca8 |
cell division cycle associated 8 |
decreases expression |
ISO |
palbociclib results in decreased expression of CDCA8 mRNA |
CTD |
PMID:22869556 |
|
NCBI chr 5:137,176,414...137,198,686
Ensembl chr 5:137,176,417...137,198,629
|
|
G |
Cdh1 |
cadherin 1 |
affects localization multiple interactions |
ISO |
palbociclib affects the localization of CDH1 protein CDH1 protein affects the reaction [palbociclib results in decreased expression of FOXM1 protein] |
CTD |
PMID:22094256 PMID:22869556 |
|
NCBI chr19:34,492,371...34,561,775
Ensembl chr19:34,492,371...34,561,775
|
|
G |
Cdh2 |
cadherin 2 |
multiple interactions increases expression |
ISO |
2-(5-benzo(1,3)dioxol-5-yl-2-tert-butyl-3H-imidazol-4-yl)-6-methylpyridine hydrochloride inhibits the reaction [palbociclib results in increased expression of CDH2 protein] |
CTD |
PMID:22869556 |
|
NCBI chr18:7,776,704...7,990,934
Ensembl chr18:7,776,704...7,990,167
|
|
G |
Cdk1 |
cyclin-dependent kinase 1 |
decreases expression |
ISO |
palbociclib analog results in decreased expression of CDK1 mRNA; palbociclib results in decreased expression of CDK1 mRNA |
CTD |
PMID:15542782 PMID:22869556 PMID:24606660 |
|
NCBI chr20:19,266,226...19,281,417
Ensembl chr20:19,266,248...19,281,408
|
|
G |
Cdk2 |
cyclin dependent kinase 2 |
decreases activity multiple interactions decreases phosphorylation decreases expression |
ISO |
palbociclib results in decreased activity of CDK2 protein palbociclib results in increased phosphorylation of and results in increased expression of CDK2 protein palbociclib results in decreased phosphorylation of CDK2 protein palbociclib results in decreased expression of CDK2 protein |
CTD |
PMID:17537993 PMID:20100483 PMID:20473330 PMID:21880723 PMID:22869556 |
|
NCBI chr 7:1,129,878...1,137,431
Ensembl chr 7:1,129,811...1,137,403
|
|
G |
Cdk4 |
cyclin-dependent kinase 4 |
decreases response to substance decreases activity multiple interactions increases expression increases response to substance |
ISO |
CDK4 protein results in decreased susceptibility to palbociclib palbociclib results in decreased activity of CDK4 protein [CDKN2A gene mutant form results in increased expression of CDK4 protein] which results in increased susceptibility to palbociclib palbociclib results in increased expression of CDK4 protein palbociclib inhibits the reaction [[CDK4 protein binds to CCND1 protein] which results in increased phosphorylation of SHOX2 protein]; palbociclib inhibits the reaction [CDC37 protein binds to CDK4 protein]; palbociclib promotes the reaction [CCND1 protein binds to CDKN1B protein binds to CDK4 protein]; palbociclib promotes the reaction [CDK4 protein binds to CCND1 protein] CDK4 protein results in increased susceptibility to palbociclib |
CTD |
PMID:20473330 PMID:22094256 PMID:22711607 PMID:22761470 PMID:22869556 PMID:23708653 PMID:24098593 PMID:24795392 PMID:29091774 More...
|
|
NCBI chr 7:62,885,647...62,889,562
Ensembl chr 7:62,883,105...62,942,403
|
|
G |
Cdk6 |
cyclin-dependent kinase 6 |
multiple interactions increases expression |
ISO |
palbociclib inhibits the reaction [[CDK6 protein binds to CCND3 protein] which results in increased phosphorylation of MEF2D protein]; palbociclib inhibits the reaction [[CDK6 protein binds to CCND3 protein] which results in increased phosphorylation of RB1 protein]; palbociclib inhibits the reaction [[CDK6 protein binds to CCND3 protein] which results in increased phosphorylation of RBL2 protein]; palbociclib inhibits the reaction [[CDK6 protein binds to CCND3 protein] which results in increased phosphorylation of SENP3 protein]; palbociclib inhibits the reaction [[CDK6 protein binds to CCND3 protein] which results in increased phosphorylation of ZEB1 protein]; palbociclib inhibits the reaction [CDC37 protein binds to CDK6 protein] palbociclib results in increased expression of CDK6 protein [CDKN2A gene mutant form results in increased expression of CDK6 protein] which results in increased susceptibility to palbociclib |
CTD |
PMID:20473330 PMID:22094256 PMID:22869556 PMID:23138228 PMID:24098593 PMID:29091774 More...
|
|
NCBI chr 4:30,637,650...30,829,688
Ensembl chr 4:30,646,460...30,829,634
|
|
G |
Cdk7 |
cyclin-dependent kinase 7 |
increases expression |
ISO |
palbociclib results in increased expression of CDK7 mRNA |
CTD |
PMID:24606660 |
|
NCBI chr 2:31,840,545...31,865,447
Ensembl chr 2:31,840,558...31,865,383
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
increases expression |
ISO |
palbociclib results in increased expression of CDKN1A protein |
CTD |
PMID:20473330 |
|
NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
|
|
G |
Cdkn1b |
cyclin-dependent kinase inhibitor 1B |
multiple interactions increases expression decreases expression |
ISO |
palbociclib promotes the reaction [CCND1 protein binds to CDKN1B protein binds to CDK4 protein] palbociclib results in increased expression of CDKN1B mRNA; palbociclib results in increased expression of CDKN1B protein palbociclib results in decreased expression of CDKN1B protein |
CTD |
PMID:17537993 PMID:20473330 |
|
NCBI chr 4:167,760,067...167,765,177
Ensembl chr 4:167,760,181...167,764,982
|
|
G |
Cdkn2a |
cyclin-dependent kinase inhibitor 2A |
affects response to substance increases response to substance multiple interactions decreases response to substance |
ISO |
CDKN2A gene modified form affects the susceptibility to palbociclib; CDKN2A gene mutant form affects the susceptibility to palbociclib; CDKN2A protein affects the susceptibility to palbociclib CDKN2A gene mutant form results in increased susceptibility to palbociclib [CDKN2A gene mutant form results in increased expression of CCND1 protein] which results in increased susceptibility to palbociclib; [CDKN2A gene mutant form results in increased expression of CCND2 protein] which results in increased susceptibility to palbociclib; [CDKN2A gene mutant form results in increased expression of CCND3 protein] which results in increased susceptibility to palbociclib; [CDKN2A gene mutant form results in increased expression of CDK4 protein] which results in increased susceptibility to palbociclib; [CDKN2A gene mutant form results in increased expression of CDK6 protein] which results in increased susceptibility to palbociclib; [CDKN2A gene mutant form results in increased susceptibility to palbociclib] which affects the activity of CASP3 protein; [CDKN2A gene mutant form results in increased susceptibility to palbociclib] which affects the activity of CASP7 protein; [CDKN2A gene mutant form results in increased susceptibility to palbociclib] which results in decreased phosphorylation of RB1 protein CDKN2A protein results in decreased susceptibility to palbociclib [CDKN2A protein co-treated with CDKN2C protein] affects the susceptibility to palbociclib |
CTD |
PMID:20534551 PMID:21278246 PMID:22711607 PMID:24098593 PMID:24495407 |
|
NCBI chr 5:103,984,949...103,992,143
Ensembl chr 5:103,984,949...104,003,149
|
|
G |
Cdkn2b |
cyclin-dependent kinase inhibitor 2B |
increases expression multiple interactions decreases response to substance |
ISO |
palbociclib results in increased expression of CDKN2B protein 2-(5-benzo(1,3)dioxol-5-yl-2-tert-butyl-3H-imidazol-4-yl)-6-methylpyridine hydrochloride inhibits the reaction [palbociclib results in increased expression of CDKN2B protein] CDKN2B protein results in decreased susceptibility to palbociclib |
CTD |
PMID:22711607 PMID:22869556 |
|
NCBI chr 5:104,009,839...104,019,082
Ensembl chr 5:104,010,680...104,019,050
|
|
G |
Cdkn2c |
cyclin-dependent kinase inhibitor 2C |
multiple interactions |
ISO |
[CDKN2A protein co-treated with CDKN2C protein] affects the susceptibility to palbociclib |
CTD |
PMID:20534551 |
|
NCBI chr 5:124,411,123...124,416,278
Ensembl chr 5:124,411,124...124,416,278
|
|
G |
Cdkn3 |
cyclin-dependent kinase inhibitor 3 |
decreases expression |
ISO |
palbociclib results in decreased expression of CDKN3 mRNA |
CTD |
PMID:22869556 |
|
NCBI chr15:20,022,522...20,033,948
Ensembl chr15:20,022,664...20,033,945
|
|
G |
Cdt1 |
chromatin licensing and DNA replication factor 1 |
decreases expression |
ISO |
palbociclib results in decreased expression of CDT1 mRNA |
CTD |
PMID:22869556 |
|
NCBI chr19:50,620,713...50,625,659
Ensembl chr19:50,620,713...50,625,659
|
|
G |
Cenpa |
centromere protein A |
decreases expression |
ISO |
palbociclib results in decreased expression of CENPA mRNA |
CTD |
PMID:22869556 |
|
NCBI chr 6:25,700,142...25,711,767
Ensembl chr 6:25,700,142...25,711,675
|
|
G |
Cenpe |
centromere protein E |
decreases expression |
ISO |
palbociclib results in decreased expression of CENPE mRNA |
CTD |
PMID:22869556 |
|
NCBI chr 2:223,637,035...223,695,692
Ensembl chr 2:223,636,998...223,695,669
|
|
G |
Cenpf |
centromere protein F |
decreases expression |
ISO |
palbociclib results in decreased expression of CENPF mRNA |
CTD |
PMID:22869556 |
|
NCBI chr13:101,184,127...101,229,714
Ensembl chr13:101,184,127...101,229,669
|
|
G |
Cenpm |
centromere protein M |
decreases expression |
ISO |
palbociclib results in decreased expression of CENPM mRNA |
CTD |
PMID:22869556 |
|
NCBI chr 7:113,748,026...113,759,296
Ensembl chr 7:113,747,516...113,764,258
|
|
G |
Cep55 |
centrosomal protein 55 |
decreases expression |
ISO |
palbociclib results in decreased expression of CEP55 mRNA |
CTD |
PMID:22869556 |
|
NCBI chr 1:235,832,823...235,848,401
Ensembl chr 1:235,832,878...235,848,394
|
|
G |
Ckap2l |
cytoskeleton associated protein 2-like |
decreases expression |
ISO |
palbociclib results in decreased expression of CKAP2L mRNA |
CTD |
PMID:22869556 |
|
NCBI chr 3:116,497,186...116,524,302
Ensembl chr 3:116,498,022...116,524,366
|
|
G |
Cpa4 |
carboxypeptidase A4 |
increases expression |
ISO |
palbociclib results in increased expression of CPA4 mRNA |
CTD |
PMID:22869556 |
|
NCBI chr 4:59,188,284...59,212,255
Ensembl chr 4:59,188,284...59,212,255
|
|
G |
Ctnnb1 |
catenin beta 1 |
multiple interactions increases expression |
ISO |
2-(5-benzo(1,3)dioxol-5-yl-2-tert-butyl-3H-imidazol-4-yl)-6-methylpyridine hydrochloride inhibits the reaction [palbociclib results in increased expression of CTNNB1 protein] |
CTD |
PMID:22869556 |
|
NCBI chr 8:120,640,008...120,667,110
Ensembl chr 8:120,639,995...120,667,111
|
|
G |
Dennd6b |
DENN domain containing 6B |
increases expression |
ISO |
palbociclib results in increased expression of DENND6B mRNA |
CTD |
PMID:22869556 |
|
NCBI chr 7:120,261,679...120,273,667
Ensembl chr 7:120,261,679...120,273,494
|
|
G |
Depdc1b |
DEP domain containing 1B |
decreases expression |
ISO |
palbociclib results in decreased expression of DEPDC1B mRNA |
CTD |
PMID:22869556 |
|
NCBI chr 2:39,891,163...39,963,779
Ensembl chr 2:39,891,481...39,963,779
|
|
G |
Dlgap5 |
DLG associated protein 5 |
decreases expression |
ISO |
palbociclib results in decreased expression of DLGAP5 mRNA |
CTD |
PMID:22869556 |
|
NCBI chr15:20,633,964...20,664,569
Ensembl chr15:20,633,966...20,664,518
|
|
G |
Donson |
DNA replication fork stabilization factor DONSON |
decreases expression |
ISO |
palbociclib results in decreased expression of DONSON mRNA |
CTD |
PMID:22869556 |
|
NCBI chr11:30,911,616...30,933,150
Ensembl chr11:30,923,239...30,932,889
|
|
G |
E2f1 |
E2F transcription factor 1 |
multiple interactions |
ISO |
palbociclib inhibits the reaction [Doxorubicin results in increased expression of E2F1 protein]; RB1 protein affects the reaction [palbociclib inhibits the reaction [Doxorubicin results in increased expression of E2F1 protein]] |
CTD |
PMID:22751436 |
|
NCBI chr 3:143,064,535...143,075,362
Ensembl chr 3:143,049,478...143,075,361
|
|
G |
E2f2 |
E2F transcription factor 2 |
multiple interactions decreases expression |
ISO |
E2F2 protein inhibits the reaction [palbociclib results in decreased expression of CCNA2 protein]; E2F2 protein inhibits the reaction [palbociclib results in decreased expression of RNR2 protein]; E2F2 protein inhibits the reaction [palbociclib results in decreased phosphorylation of RB1 protein] palbociclib results in decreased expression of E2F2 mRNA |
CTD |
PMID:20100483 PMID:20473330 PMID:22869556 |
|
NCBI chr 5:148,399,193...148,422,595
Ensembl chr 5:148,399,642...148,421,217
|
|
G |
Eln |
elastin |
increases expression |
ISO |
palbociclib results in increased expression of ELN protein |
CTD |
PMID:21880723 |
|
NCBI chr12:21,968,544...22,011,929
Ensembl chr12:21,968,544...22,011,928
|
|
G |
Exo1 |
exonuclease 1 |
decreases expression |
ISO |
palbociclib results in decreased expression of EXO1 mRNA |
CTD |
PMID:22869556 |
|
NCBI chr13:87,809,725...87,834,654
Ensembl chr13:87,809,810...87,834,654
|
|
G |
Ezh2 |
enhancer of zeste 2 polycomb repressive complex 2 subunit |
decreases expression |
ISO |
palbociclib results in decreased expression of EZH2 mRNA; palbociclib results in decreased expression of EZH2 protein |
CTD |
PMID:20948315 PMID:22869556 PMID:24736461 |
|
NCBI chr 4:76,624,399...76,687,362
Ensembl chr 4:76,624,399...76,687,362
|
|
G |
F3 |
coagulation factor III, tissue factor |
increases expression |
ISO |
palbociclib results in increased expression of F3 mRNA |
CTD |
PMID:22869556 |
|
NCBI chr 2:209,827,061...209,838,666
Ensembl chr 2:209,826,959...209,838,668
|
|
G |
Fam111a |
FAM111 trypsin like peptidase A |
decreases expression |
ISO |
palbociclib results in decreased expression of FAM111A mRNA |
CTD |
PMID:22869556 |
|
NCBI chr 1:209,640,865...209,656,551
Ensembl chr 1:209,640,953...209,656,547
|
|
G |
Fam83d |
family with sequence similarity 83, member D |
decreases expression |
ISO |
palbociclib results in decreased expression of FAM83D mRNA |
CTD |
PMID:22869556 |
|
NCBI chr 3:147,421,941...147,441,211
Ensembl chr 3:147,421,908...147,441,192
|
|
G |
Fance |
FA complementation group E |
decreases expression |
ISO |
palbociclib results in decreased expression of FANCE mRNA |
CTD |
PMID:28620137 |
|
NCBI chr20:6,369,416...6,386,631
Ensembl chr20:6,375,573...6,386,631
|
|
G |
Fanci |
FA complementation group I |
decreases expression |
ISO |
palbociclib results in decreased expression of FANCI mRNA |
CTD |
PMID:22869556 |
|
NCBI chr 1:133,327,264...133,383,661
Ensembl chr 1:133,327,297...133,383,640
|
|
G |
Fbxo5 |
F-box protein 5 |
decreases expression |
ISO |
palbociclib results in decreased expression of FBXO5 mRNA |
CTD |
PMID:22869556 |
|
NCBI chr 1:42,196,068...42,202,437
Ensembl chr 1:42,196,068...42,202,437
|
|
G |
Fen1 |
flap structure-specific endonuclease 1 |
decreases expression |
ISO |
palbociclib results in decreased expression of FEN1 mRNA |
CTD |
PMID:22869556 |
|
NCBI chr 1:206,845,126...206,849,821
Ensembl chr 1:206,844,884...206,850,003
|
|
G |
Flt3 |
Fms related receptor tyrosine kinase 3 |
decreases expression affects response to substance decreases phosphorylation multiple interactions |
ISO |
palbociclib results in decreased expression of FLT3 mRNA; palbociclib results in decreased expression of FLT3 protein FLT3 protein affects the susceptibility to palbociclib palbociclib results in decreased phosphorylation of FLT3 protein [FLT3 protein affects the susceptibility to palbociclib] which results in decreased expression of FLT3 protein |
CTD |
PMID:27099147 |
|
NCBI chr12:7,623,658...7,699,474
Ensembl chr12:7,623,930...7,699,474
|
|
G |
Foxm1 |
forkhead box M1 |
multiple interactions decreases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [palbociclib results in decreased expression of FOXM1 protein]; CDH1 protein affects the reaction [palbociclib results in decreased expression of FOXM1 protein]; palbociclib results in decreased expression of and results in decreased activity of FOXM1 protein palbociclib results in decreased expression of FOXM1 mRNA |
CTD |
PMID:22094256 PMID:22869556 |
|
NCBI chr 4:161,639,561...161,652,012
Ensembl chr 4:161,638,816...161,650,684
|
|
G |
Gins2 |
GINS complex subunit 2 |
decreases expression |
ISO |
palbociclib results in decreased expression of GINS2 mRNA |
CTD |
PMID:22869556 |
|
NCBI chr19:48,626,770...48,639,523
Ensembl chr19:48,626,770...48,639,339
|
|
G |
Gls |
glutaminase |
increases expression |
ISO |
palbociclib results in increased expression of GLS mRNA |
CTD |
PMID:28620137 |
|
NCBI chr 9:49,344,616...49,416,900
Ensembl chr 9:49,344,781...49,416,900
|
|
G |
Gmnn |
geminin, DNA replication inhibitor |
decreases expression |
ISO |
palbociclib results in decreased expression of GMNN mRNA |
CTD |
PMID:22869556 |
|
NCBI chr17:40,301,771...40,310,054
Ensembl chr17:40,301,808...40,310,054
|
|
G |
Gpsm2 |
G-protein signaling modulator 2 |
decreases expression |
ISO |
palbociclib results in decreased expression of GPSM2 mRNA |
CTD |
PMID:22869556 |
|
NCBI chr 2:196,327,149...196,375,322
Ensembl chr 2:196,327,149...196,375,154
|
|
G |
Gpt |
glutamic--pyruvic transaminase |
increases secretion |
ISO |
palbociclib results in increased secretion of GPT protein |
CTD |
PMID:29655783 |
|
NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494
|
|
G |
H2ax |
H2A.X variant histone |
multiple interactions decreases phosphorylation |
ISO |
Doxorubicin inhibits the reaction [palbociclib results in decreased phosphorylation of H2AX protein]; palbociclib inhibits the reaction [Camptothecin results in increased expression of H2AX protein]; palbociclib inhibits the reaction [Carboplatin results in increased expression of H2AX protein]; palbociclib inhibits the reaction [Doxorubicin results in increased expression of H2AX protein]; palbociclib inhibits the reaction [Etoposide results in increased expression of H2AX protein]; palbociclib inhibits the reaction [Paclitaxel results in increased expression of H2AX protein]; RB1 protein affects the reaction [palbociclib results in decreased phosphorylation of H2AX protein] |
CTD |
PMID:22302033 PMID:22751436 |
|
NCBI chr 8:44,671,927...44,673,257
Ensembl chr 8:44,671,786...44,673,239
|
|
G |
H4c3 |
H4 clustered histone 3 |
decreases expression |
ISO |
palbociclib results in decreased expression of H4C3 mRNA |
CTD |
PMID:22869556 |
|
|
|
G |
Hjurp |
Holliday junction recognition protein |
decreases expression |
ISO |
palbociclib results in decreased expression of HJURP mRNA |
CTD |
PMID:22869556 |
|
NCBI chr 9:88,853,379...88,867,730
Ensembl chr 9:88,853,386...88,867,728
|
|
G |
Hmgb2 |
high mobility group box 2 |
decreases expression |
ISO |
palbociclib results in decreased expression of HMGB2 mRNA |
CTD |
PMID:22869556 |
|
NCBI chr16:32,710,651...32,713,230
Ensembl chr16:32,710,658...32,713,140
|
|
G |
Hmmr |
hyaluronan-mediated motility receptor |
decreases expression |
ISO |
palbociclib results in decreased expression of HMMR mRNA |
CTD |
PMID:22869556 |
|
NCBI chr10:25,132,933...25,163,029
Ensembl chr10:25,132,977...25,163,060
|
|
G |
Igf1r |
insulin-like growth factor 1 receptor |
multiple interactions |
ISO |
[BMS 754807 co-treated with palbociclib] results in decreased phosphorylation of IGF1R protein |
CTD |
PMID:24986516 |
|
NCBI chr 1:121,549,839...121,838,545
Ensembl chr 1:121,550,743...121,831,777
|
|
G |
Il20rb |
interleukin 20 receptor subunit beta |
increases expression |
ISO |
palbociclib results in increased expression of IL20RB mRNA |
CTD |
PMID:22869556 |
|
NCBI chr 8:100,979,085...101,010,829
Ensembl chr 8:100,980,383...101,009,942
|
|
G |
Incenp |
inner centromere protein |
decreases expression |
ISO |
palbociclib results in decreased expression of INCENP mRNA |
CTD |
PMID:22869556 |
|
NCBI chr 1:206,520,655...206,550,575
Ensembl chr 1:206,523,380...206,553,265
|
|
G |
Kif11 |
kinesin family member 11 |
decreases expression |
ISO |
palbociclib results in decreased expression of KIF11 mRNA |
CTD |
PMID:22869556 |
|
NCBI chr 1:235,124,371...235,176,760
Ensembl chr 1:235,124,316...235,176,766
|
|
G |
Kif14 |
kinesin family member 14 |
decreases expression |
ISO |
palbociclib results in decreased expression of KIF14 mRNA |
CTD |
PMID:22869556 |
|
NCBI chr13:47,926,975...47,990,598
Ensembl chr13:47,927,044...47,989,164
|
|
G |
Kif15 |
kinesin family member 15 |
decreases expression |
ISO |
palbociclib results in decreased expression of KIF15 mRNA |
CTD |
PMID:22869556 |
|
NCBI chr 8:122,601,888...122,672,750
Ensembl chr 8:122,601,897...122,672,750
|
|
G |
Kif20a |
kinesin family member 20A |
decreases expression |
ISO |
palbociclib results in decreased expression of KIF20A mRNA |
CTD |
PMID:22869556 |
|
NCBI chr18:26,230,294...26,238,780
Ensembl chr18:26,230,230...26,238,780
|
|
G |
Kif23 |
kinesin family member 23 |
decreases expression |
ISO |
palbociclib results in decreased expression of KIF23 mRNA |
CTD |
PMID:22869556 |
|
NCBI chr 8:62,397,908...62,425,162
Ensembl chr 8:62,397,948...62,425,072
|
|
G |
Kif2c |
kinesin family member 2C |
decreases expression |
ISO |
palbociclib results in decreased expression of KIF2C mRNA |
CTD |
PMID:22869556 |
|
NCBI chr 5:130,637,347...130,662,680
Ensembl chr 5:130,637,347...130,662,637
|
|
G |
Kif4a |
kinesin family member 4A |
decreases expression |
ISO |
palbociclib results in decreased expression of KIF4A mRNA |
CTD |
PMID:22869556 |
|
NCBI chr X:65,721,724...65,824,151
Ensembl chr X:65,721,779...65,824,139
|
|
G |
Kifc1 |
kinesin family member C1 |
decreases expression |
ISO |
palbociclib results in decreased expression of KIFC1 mRNA |
CTD |
PMID:22869556 |
|
NCBI chr20:4,998,832...5,017,107
Ensembl chr20:4,999,047...5,017,105
|
|
G |
Knstrn |
kinetochore-localized astrin/SPAG5 binding protein |
decreases expression |
ISO |
palbociclib results in decreased expression of KNSTRN mRNA |
CTD |
PMID:22869556 |
|
NCBI chr 3:105,800,762...105,820,555
Ensembl chr 3:105,800,954...105,820,715
|
|
G |
Kpna2 |
karyopherin subunit alpha 2 |
decreases expression |
ISO |
palbociclib results in decreased expression of KPNA2 mRNA |
CTD |
PMID:22869556 |
|
NCBI chr10:91,933,951...91,946,115
Ensembl chr10:91,933,951...91,946,150
|
|
G |
Lama3 |
laminin subunit alpha 3 |
increases expression |
ISO |
palbociclib results in increased expression of LAMA3 mRNA |
CTD |
PMID:22869556 |
|
NCBI chr18:3,523,168...3,751,722
Ensembl chr18:3,523,133...3,751,353
|
|
G |
Lamb3 |
laminin subunit beta 3 |
increases expression |
ISO |
palbociclib results in increased expression of LAMB3 mRNA |
CTD |
PMID:22869556 |
|
NCBI chr13:104,833,810...104,875,405
Ensembl chr13:104,833,873...104,875,405
|
|
G |
Lamc2 |
laminin subunit gamma 2 |
increases expression |
ISO |
palbociclib results in increased expression of LAMC2 mRNA |
CTD |
PMID:22869556 |
|
NCBI chr13:65,284,664...65,344,200
Ensembl chr13:65,284,664...65,344,200
|
|
G |
Lmnb1 |
lamin B1 |
decreases expression |
ISO |
palbociclib results in decreased expression of LMNB1 mRNA |
CTD |
PMID:22869556 |
|
NCBI chr18:50,175,861...50,215,210
Ensembl chr18:50,175,874...50,214,502
|
|
G |
Mcm10 |
minichromosome maintenance 10 replication initiation factor |
decreases expression |
ISO |
palbociclib results in decreased expression of MCM10 mRNA |
CTD |
PMID:22869556 |
|
NCBI chr17:73,263,788...73,288,346
Ensembl chr17:73,266,095...73,287,364
|
|
G |
Mcm7 |
minichromosome maintenance complex component 7 |
multiple interactions decreases expression |
ISO |
RB1 protein affects the reaction [palbociclib results in decreased expression of MCM7 protein] palbociclib results in decreased expression of MCM7 mRNA; palbociclib results in decreased expression of MCM7 protein |
CTD |
PMID:20473330 PMID:22869556 |
|
NCBI chr12:17,042,207...17,049,470
Ensembl chr12:17,042,212...17,050,063
|
|
G |
Mef2d |
myocyte enhancer factor 2D |
multiple interactions |
ISO |
palbociclib inhibits the reaction [[CDK6 protein binds to CCND3 protein] which results in increased phosphorylation of MEF2D protein] |
CTD |
PMID:22094256 |
|
NCBI chr 2:173,606,054...173,635,620
Ensembl chr 2:173,606,490...173,634,457
|
|
G |
Melk |
maternal embryonic leucine zipper kinase |
decreases expression |
ISO |
palbociclib results in decreased expression of MELK mRNA |
CTD |
PMID:22869556 |
|
NCBI chr 5:58,540,393...58,600,937
Ensembl chr 5:58,540,449...58,600,937
|
|
G |
Mki67 |
marker of proliferation Ki-67 |
multiple interactions decreases expression |
ISO |
Doxorubicin promotes the reaction [palbociclib results in decreased expression of MKI67 protein]; RB1 protein affects the reaction [palbociclib results in decreased expression of MKI67 protein] |
CTD |
PMID:15542782 PMID:22170262 PMID:22383795 PMID:22751436 PMID:23708653 PMID:26318986 PMID:28620137 More...
|
|
NCBI chr 1:190,496,319...190,522,983
Ensembl chr 1:190,496,319...190,522,762
|
|
G |
Mxd4 |
Max dimerization protein 4 |
increases expression |
ISO |
palbociclib results in increased expression of MXD4 mRNA |
CTD |
PMID:22869556 |
|
NCBI chr14:76,562,105...76,576,224
Ensembl chr14:76,561,774...76,576,221
|
|
G |
Myc |
MYC proto-oncogene, bHLH transcription factor |
decreases expression |
ISO |
palbociclib results in decreased expression of MYC protein |
CTD |
PMID:27099147 |
|
NCBI chr 7:93,593,705...93,598,633
Ensembl chr 7:93,593,705...93,598,630
|
|
G |
Ncapd2 |
non-SMC condensin I complex, subunit D2 |
decreases expression |
ISO |
palbociclib results in decreased expression of NCAPD2 mRNA |
CTD |
PMID:22869556 |
|
NCBI chr 4:157,968,814...157,992,314
Ensembl chr 4:157,968,815...157,992,020
|
|
G |
Ncapg |
non-SMC condensin I complex, subunit G |
decreases expression |
ISO |
palbociclib results in decreased expression of NCAPG mRNA |
CTD |
PMID:22869556 |
|
NCBI chr14:65,404,235...65,432,902
Ensembl chr14:65,404,163...65,432,902
|
|
G |
Ncapg2 |
non-SMC condensin II complex, subunit G2 |
decreases expression |
ISO |
palbociclib results in decreased expression of NCAPG2 mRNA |
CTD |
PMID:22869556 |
|
NCBI chr 6:137,342,449...137,418,083
Ensembl chr 6:137,342,943...137,415,159
|
|
G |
Ndc80 |
NDC80 kinetochore complex component |
decreases expression |
ISO |
palbociclib results in decreased expression of NDC80 mRNA |
CTD |
PMID:22869556 |
|
NCBI chr 9:111,407,191...111,440,921
Ensembl chr 9:111,407,191...111,440,924
|
|
G |
Nek2 |
NIMA-related kinase 2 |
decreases expression |
ISO |
palbociclib results in decreased expression of NEK2 mRNA |
CTD |
PMID:22869556 |
|
NCBI chr13:103,405,818...103,419,063
Ensembl chr13:103,405,819...103,419,051
|
|
G |
Nusap1 |
nucleolar and spindle associated protein 1 |
decreases expression |
ISO |
palbociclib results in decreased expression of NUSAP1 mRNA |
CTD |
PMID:22869556 |
|
NCBI chr 3:106,603,273...106,633,624
Ensembl chr 3:106,603,289...106,633,624
|
|
G |
Oip5 |
Opa interacting protein 5 |
decreases expression |
ISO |
palbociclib results in decreased expression of OIP5 mRNA |
CTD |
PMID:22869556 |
|
NCBI chr 3:106,593,746...106,603,281
Ensembl chr 3:106,593,760...106,603,250
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
multiple interactions |
ISO |
[palbociclib results in increased susceptibility to idelalisib] which results in increased cleavage of PARP1 protein; palbociclib inhibits the reaction [Doxorubicin results in increased cleavage of PARP1 protein]; RB1 protein affects the reaction [palbociclib inhibits the reaction [Doxorubicin results in increased cleavage of PARP1 protein]] |
CTD |
PMID:22751436 PMID:23676220 |
|
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Pbk |
PDZ binding kinase |
decreases expression |
ISO |
palbociclib results in decreased expression of PBK mRNA |
CTD |
PMID:22869556 |
|
NCBI chr15:40,022,873...40,034,014
Ensembl chr15:40,023,002...40,034,014
|
|
G |
Pclaf |
PCNA clamp associated factor |
decreases expression |
ISO |
palbociclib results in decreased expression of PCLAF mRNA |
CTD |
PMID:22869556 |
|
NCBI chr 8:66,420,673...66,432,568
Ensembl chr 8:66,420,587...66,432,994 Ensembl chr 8:66,420,587...66,432,994
|
|
G |
Pcna |
proliferating cell nuclear antigen |
decreases expression |
ISO |
palbociclib results in decreased expression of PCNA mRNA; palbociclib results in decreased expression of PCNA protein |
CTD |
PMID:20473330 PMID:22869556 |
|
NCBI chr 3:119,499,039...119,502,911
Ensembl chr 3:119,498,810...119,502,995
|
|
G |
Pdgfb |
platelet derived growth factor subunit B |
multiple interactions |
ISO |
palbociclib inhibits the reaction [[PDGFB protein binds to PDGFB protein] inhibits the reaction [RB1 protein binds to SP1 protein]] |
CTD |
PMID:21880723 |
|
NCBI chr 7:111,539,444...111,557,984
Ensembl chr 7:111,540,345...111,557,984
|
|
G |
Phf19 |
PHD finger protein 19 |
decreases expression |
ISO |
palbociclib results in decreased expression of PHF19 mRNA |
CTD |
PMID:22869556 |
|
NCBI chr 3:18,175,281...18,197,289
Ensembl chr 3:18,175,282...18,196,405
|
|
G |
Pim1 |
Pim-1 proto-oncogene, serine/threonine kinase |
decreases expression |
ISO |
palbociclib results in decreased expression of PIM1 mRNA |
CTD |
PMID:27099147 |
|
NCBI chr20:7,554,921...7,559,174
Ensembl chr20:7,554,921...7,559,174
|
|
G |
Pimreg |
PICALM interacting mitotic regulator |
decreases expression |
ISO |
palbociclib results in decreased expression of PIMREG mRNA |
CTD |
PMID:22869556 |
|
NCBI chr10:56,669,603...56,674,540
Ensembl chr10:56,669,675...56,674,791
|
|
G |
Plk1 |
polo-like kinase 1 |
decreases expression multiple interactions |
ISO |
palbociclib results in decreased expression of PLK1 mRNA palbociclib inhibits the reaction [RBL1 protein binds to PLK1 promoter]; RB1 protein affects the reaction [palbociclib inhibits the reaction [RBL1 protein binds to PLK1 promoter]] |
CTD |
PMID:20100483 PMID:22869556 |
|
NCBI chr 1:176,716,420...176,726,400
Ensembl chr 1:176,716,420...176,726,400
|
|
G |
Pola2 |
DNA polymerase alpha 2, accessory subunit |
decreases expression |
ISO |
palbociclib results in decreased expression of POLA2 mRNA |
CTD |
PMID:22869556 |
|
NCBI chr 1:203,227,183...203,251,350
Ensembl chr 1:203,203,388...203,251,348
|
|
G |
Pole2 |
DNA polymerase epsilon 2, accessory subunit |
decreases expression |
ISO |
palbociclib results in decreased expression of POLE2 mRNA |
CTD |
PMID:22869556 |
|
NCBI chr 6:87,674,702...87,712,723
Ensembl chr 6:87,674,702...87,699,305
|
|
G |
Porcn |
porcupine O-acyltransferase |
increases expression |
ISO |
palbociclib results in increased expression of PORCN mRNA |
CTD |
PMID:22869556 |
|
NCBI chr X:14,285,864...14,298,481
Ensembl chr X:14,285,871...14,298,481
|
|
G |
Prc1 |
protein regulator of cytokinesis 1 |
decreases expression |
ISO |
palbociclib results in decreased expression of PRC1 mRNA |
CTD |
PMID:22869556 |
|
NCBI chr 1:134,250,086...134,271,765
Ensembl chr 1:134,250,081...134,271,765
|
|
G |
Prim1 |
DNA primase subunit 1 |
decreases expression |
ISO |
palbociclib results in decreased expression of PRIM1 mRNA |
CTD |
PMID:22869556 |
|
NCBI chr 7:446,342...462,526
Ensembl chr 7:431,805...462,526
|
|
G |
Prr11 |
proline rich 11 |
decreases expression |
ISO |
palbociclib results in decreased expression of PRR11 mRNA |
CTD |
PMID:22869556 |
|
NCBI chr10:71,898,858...71,943,325
Ensembl chr10:71,901,202...71,921,012
|
|
G |
Prss23 |
serine protease 23 |
increases expression |
ISO |
palbociclib results in increased expression of PRSS23 mRNA |
CTD |
PMID:22869556 |
|
NCBI chr 1:143,402,725...143,422,182
Ensembl chr 1:143,401,396...143,422,091
|
|
G |
Psrc1 |
proline and serine rich coiled-coil 1 |
decreases expression |
ISO |
palbociclib results in decreased expression of PSRC1 mRNA |
CTD |
PMID:22869556 |
|
NCBI chr 2:196,022,361...196,026,874
Ensembl chr 2:196,022,361...196,026,874
|
|
G |
Pttg1 |
PTTG1 regulator of sister chromatid separation, securin |
decreases expression |
ISO |
palbociclib results in decreased expression of PTTG1 mRNA |
CTD |
PMID:22869556 PMID:28620137 |
|
NCBI chr10:27,893,466...27,904,965
Ensembl chr10:27,893,689...27,904,837
|
|
G |
Racgap1 |
Rac GTPase-activating protein 1 |
decreases expression |
ISO |
palbociclib results in decreased expression of RACGAP1 mRNA |
CTD |
PMID:22869556 |
|
NCBI chr 7:130,750,936...130,780,891
Ensembl chr 7:130,750,936...130,780,831
|
|
G |
Rad51ap1 |
RAD51 associated protein 1 |
decreases expression |
ISO |
palbociclib results in decreased expression of RAD51AP1 mRNA |
CTD |
PMID:22869556 |
|
NCBI chr 4:159,759,454...159,772,524
Ensembl chr 4:159,759,459...159,772,524
|
|
G |
Ranbp1 |
RAN binding protein 1 |
decreases expression |
ISO |
palbociclib results in decreased expression of RANBP1 mRNA |
CTD |
PMID:28620137 |
|
NCBI chr11:82,742,603...82,750,836
Ensembl chr11:82,742,600...82,750,838
|
|
G |
Rb1 |
RB transcriptional corepressor 1 |
affects phosphorylation decreases expression increases response to substance multiple interactions affects response to substance decreases response to substance affects reaction increases phosphorylation decreases phosphorylation |
ISO |
palbociclib affects the phosphorylation of RB1 protein palbociclib results in decreased expression of RB1 mRNA; palbociclib results in decreased expression of RB1 protein RB1 protein results in increased susceptibility to palbociclib [CDKN2A gene mutant form results in increased susceptibility to palbociclib] which results in decreased phosphorylation of RB1 protein RB1 protein affects the susceptibility to palbociclib BMS 754807 promotes the reaction [palbociclib results in decreased phosphorylation of RB1 protein]; E2F2 protein inhibits the reaction [palbociclib results in decreased phosphorylation of RB1 protein]; palbociclib affects the reaction [RB1 mutant form results in increased expression of RBL2 protein]; palbociclib inhibits the reaction [[CDK6 protein binds to CCND3 protein] which results in increased phosphorylation of RB1 protein]; palbociclib inhibits the reaction [[PDGFB protein binds to PDGFB protein] inhibits the reaction [RB1 protein binds to SP1 protein]]; palbociclib inhibits the reaction [bis(4-hydroxyphenyl)sulfone results in increased phosphorylation of RB1 protein]; palbociclib promotes the reaction [RB1 protein binds to CCNA2 promoter]; palbociclib promotes the reaction [RB1 protein binds to SP1 protein]; palbociclib results in decreased phosphorylation of and results in decreased expression of RB1 protein; RB1 protein affects the reaction [palbociclib inhibits the reaction [Doxorubicin results in increased cleavage of PARP1 protein]]; RB1 protein affects the reaction [palbociclib inhibits the reaction [Doxorubicin results in increased expression of CCNA2 protein]]; RB1 protein affects the reaction [palbociclib inhibits the reaction [Doxorubicin results in increased expression of E2F1 protein]]; RB1 protein affects the reaction [palbociclib inhibits the reaction [Doxorubicin results in increased expression of TOP2A protein]]; RB1 protein affects the reaction [palbociclib inhibits the reaction [RBL1 protein binds to CCNA2 promoter]]; RB1 protein affects the reaction [palbociclib inhibits the reaction [RBL1 protein binds to PLK1 promoter]]; RB1 protein affects the reaction [palbociclib inhibits the reaction [RBL1 protein binds to RNR2 promoter]]; RB1 protein affects the reaction [palbociclib promotes the reaction [Cycloheximide results in decreased expression of RBL1 protein]]; RB1 protein affects the reaction [palbociclib results in decreased expression of CCNA2 protein]; RB1 protein affects the reaction [palbociclib results in decreased expression of MCM7 protein]; RB1 protein affects the reaction [palbociclib results in decreased expression of MKI67 protein]; RB1 protein affects the reaction [palbociclib results in decreased expression of RBL1 protein]; RB1 protein affects the reaction [palbociclib results in decreased phosphorylation of H2AX protein]; RB1 protein affects the reaction [palbociclib results in decreased phosphorylation of RB1 protein] RB1 gene mutant form results in decreased susceptibility to palbociclib; RB1 mutant form results in decreased susceptibility to palbociclib RB1 protein affects the reaction palbociclib palbociclib results in increased phosphorylation of RB1 protein |
CTD |
PMID:15542782 PMID:16690963 PMID:17537993 PMID:19435910 PMID:19874578 PMID:20100483 PMID:20354191 PMID:20473330 PMID:20534551 PMID:21217777 PMID:21278246 PMID:21367843 PMID:21593195 PMID:21880723 PMID:22094256 PMID:22170262 PMID:22383795 PMID:22751436 PMID:22761470 PMID:22869556 PMID:23138228 PMID:23676220 PMID:23708653 PMID:24098593 PMID:24495407 PMID:24736461 PMID:24986516 PMID:25221644 PMID:26174628 PMID:26318986 PMID:26873845 PMID:28620137 PMID:30684532 More...
|
|
NCBI chr15:48,371,295...48,502,473
Ensembl chr15:48,371,296...48,502,302
|
|
G |
Rbl1 |
RB transcriptional corepressor like 1 |
multiple interactions decreases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [palbociclib results in decreased expression of RBL1 protein]; palbociclib inhibits the reaction [RBL1 protein binds to CCNA2 promoter]; palbociclib inhibits the reaction [RBL1 protein binds to PLK1 promoter]; palbociclib inhibits the reaction [RBL1 protein binds to RNR2 promoter]; palbociclib promotes the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased ubiquitination of RBL1 protein]; palbociclib promotes the reaction [Cycloheximide results in decreased expression of RBL1 protein]; palbociclib results in decreased phosphorylation of and results in decreased expression of RBL1 protein; RB1 protein affects the reaction [palbociclib inhibits the reaction [RBL1 protein binds to CCNA2 promoter]]; RB1 protein affects the reaction [palbociclib inhibits the reaction [RBL1 protein binds to PLK1 promoter]]; RB1 protein affects the reaction [palbociclib inhibits the reaction [RBL1 protein binds to RNR2 promoter]]; RB1 protein affects the reaction [palbociclib promotes the reaction [Cycloheximide results in decreased expression of RBL1 protein]]; RB1 protein affects the reaction [palbociclib results in decreased expression of RBL1 protein] palbociclib results in decreased expression of RBL1 mRNA; palbociclib results in decreased expression of RBL1 protein |
CTD |
PMID:20100483 PMID:20473330 |
|
NCBI chr 3:145,806,160...145,869,434
Ensembl chr 3:145,807,095...145,869,330
|
|
G |
Rbl2 |
RB transcriptional corepressor like 2 |
multiple interactions decreases phosphorylation |
ISO |
palbociclib affects the reaction [RB1 mutant form results in increased expression of RBL2 protein]; palbociclib inhibits the reaction [[CDK6 protein binds to CCND3 protein] which results in increased phosphorylation of RBL2 protein]; palbociclib results in decreased phosphorylation of and results in increased expression of RBL2 protein; palbociclib results in increased expression of and results in increased stability of RBL2 protein palbociclib results in decreased phosphorylation of RBL2 protein |
CTD |
PMID:20100483 PMID:20473330 PMID:22094256 PMID:26174628 |
|
NCBI chr19:15,876,852...15,923,632
Ensembl chr19:15,876,853...15,923,572
|
|
G |
Rdh5 |
retinol dehydrogenase 5 |
increases expression |
ISO |
palbociclib results in increased expression of RDH5 mRNA |
CTD |
PMID:22869556 |
|
NCBI chr 7:1,340,545...1,347,361
Ensembl chr 7:1,340,934...1,351,558
|
|
G |
Rfc5 |
replication factor C subunit 5 |
decreases expression |
ISO |
palbociclib results in decreased expression of RFC5 mRNA |
CTD |
PMID:22869556 |
|
NCBI chr12:39,207,484...39,217,041
Ensembl chr12:39,207,484...39,217,312
|
|
G |
Rps29 |
ribosomal protein S29 |
increases expression |
ISO |
palbociclib results in increased expression of RPS29 mRNA |
CTD |
PMID:22869556 |
|
NCBI chr 6:87,635,229...87,636,605
Ensembl chr 6:87,635,230...87,636,636
|
|
G |
Rps6kb1 |
ribosomal protein S6 kinase B1 |
multiple interactions |
ISO |
palbociclib promotes the reaction [BMS 754807 results in decreased phosphorylation of RPS6KB1 protein] |
CTD |
PMID:24986516 |
|
NCBI chr10:71,323,777...71,367,908
Ensembl chr10:71,323,777...71,367,908
|
|
G |
Rrm1 |
ribonucleotide reductase catalytic subunit M1 |
decreases expression |
ISO |
palbociclib results in decreased expression of RRM1 mRNA |
CTD |
PMID:22869556 |
|
NCBI chr 1:156,823,960...156,848,262
Ensembl chr 1:156,823,960...156,848,261
|
|
G |
Rrm2 |
ribonucleotide reductase regulatory subunit M2 |
decreases expression |
ISO |
palbociclib results in decreased expression of RRM2 mRNA |
CTD |
PMID:22869556 |
|
NCBI chr 6:41,339,858...41,346,774
Ensembl chr 6:41,340,557...41,346,773
|
|
G |
Sapcd2 |
suppressor APC domain containing 2 |
decreases expression |
ISO |
palbociclib results in decreased expression of SAPCD2 mRNA |
CTD |
PMID:22869556 |
|
NCBI chr 3:8,186,089...8,195,119
Ensembl chr 3:8,187,266...8,192,546
|
|
G |
Senp3 |
SUMO specific peptidase 3 |
multiple interactions |
ISO |
palbociclib inhibits the reaction [[CDK6 protein binds to CCND3 protein] which results in increased phosphorylation of SENP3 protein] |
CTD |
PMID:22094256 |
|
NCBI chr10:54,390,698...54,399,590
Ensembl chr10:54,390,694...54,399,593
|
|
G |
Serpine1 |
serpin family E member 1 |
increases expression |
ISO |
palbociclib results in increased expression of SERPINE1 mRNA |
CTD |
PMID:22869556 |
|
NCBI chr12:19,601,272...19,611,657
Ensembl chr12:19,601,272...19,611,657
|
|
G |
Shox2 |
short stature homeobox 2 |
multiple interactions |
ISO |
palbociclib inhibits the reaction [[CDK4 protein binds to CCND1 protein] which results in increased phosphorylation of SHOX2 protein] |
CTD |
PMID:22094256 |
|
NCBI chr 2:151,217,049...151,227,180
Ensembl chr 2:151,217,552...151,227,143
|
|
G |
Slc16a4 |
solute carrier family 16, member 4 |
increases expression |
ISO |
palbociclib results in increased expression of SLC16A4 mRNA |
CTD |
PMID:22869556 |
|
NCBI chr 2:194,911,075...194,933,162
Ensembl chr 2:194,911,236...194,933,117
|
|
G |
Smc4 |
structural maintenance of chromosomes 4 |
decreases expression |
ISO |
palbociclib results in decreased expression of SMC4 mRNA |
CTD |
PMID:22869556 |
|
NCBI chr 2:153,240,243...153,268,722
Ensembl chr 2:153,240,283...153,271,571
|
|
G |
Snai2 |
snail family transcriptional repressor 2 |
multiple interactions increases expression |
ISO |
2-(5-benzo(1,3)dioxol-5-yl-2-tert-butyl-3H-imidazol-4-yl)-6-methylpyridine hydrochloride inhibits the reaction [palbociclib results in increased expression of SNAI2 protein] |
CTD |
PMID:22869556 |
|
NCBI chr11:86,183,800...86,186,109
Ensembl chr11:86,181,909...86,186,200
|
|
G |
Sp1 |
Sp1 transcription factor |
multiple interactions |
ISO |
palbociclib inhibits the reaction [[PDGFB protein binds to PDGFB protein] inhibits the reaction [RB1 protein binds to SP1 protein]]; palbociclib promotes the reaction [RB1 protein binds to SP1 protein] |
CTD |
PMID:21880723 |
|
NCBI chr 7:133,541,302...133,571,961
Ensembl chr 7:133,541,491...133,571,961
|
|
G |
Sparc |
secreted protein acidic and cysteine rich |
increases expression |
ISO |
palbociclib results in increased expression of SPARC mRNA |
CTD |
PMID:28620137 |
|
NCBI chr10:39,516,394...39,538,252
Ensembl chr10:39,516,406...39,538,396
|
|
G |
Spc24 |
SPC24 component of NDC80 kinetochore complex |
decreases expression |
ISO |
palbociclib results in decreased expression of SPC24 mRNA |
CTD |
PMID:22869556 |
|
NCBI chr 8:20,300,315...20,305,354
Ensembl chr 8:20,300,319...20,305,310
|
|
G |
Spc25 |
SPC25 component of NDC80 kinetochore complex |
decreases expression |
ISO |
palbociclib results in decreased expression of SPC25 mRNA |
CTD |
PMID:22869556 |
|
NCBI chr 3:53,930,013...53,988,940
Ensembl chr 3:53,975,704...53,988,959
|
|
G |
Stil |
STIL, centriolar assembly protein |
decreases expression |
ISO |
palbociclib results in decreased expression of STIL mRNA |
CTD |
PMID:22869556 |
|
NCBI chr 5:128,520,837...128,573,732
Ensembl chr 5:128,520,953...128,573,730
|
|
G |
Stmn1 |
stathmin 1 |
decreases expression |
ISO |
palbociclib results in decreased expression of STMN1 mRNA |
CTD |
PMID:22869556 |
|
NCBI chr 5:146,680,757...146,687,154
Ensembl chr 5:146,681,436...146,687,154
|
|
G |
Tacc3 |
transforming, acidic coiled-coil containing protein 3 |
decreases expression |
ISO |
palbociclib results in decreased expression of TACC3 mRNA |
CTD |
PMID:28620137 |
|
NCBI chr14:77,051,209...77,065,343
Ensembl chr14:77,051,215...77,065,219
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
increases activity |
ISO |
palbociclib results in increased activity of TGFB1 protein |
CTD |
PMID:22869556 |
|
NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
|
|
G |
Tk1 |
thymidine kinase 1 |
decreases expression |
ISO |
palbociclib analog results in decreased expression of TK1 mRNA; palbociclib results in decreased expression of TK1 mRNA; palbociclib results in decreased expression of TK1 protein |
CTD |
PMID:15542782 PMID:22170262 PMID:22869556 |
|
NCBI chr10:103,034,755...103,046,125
Ensembl chr10:103,031,521...103,046,920
|
|
G |
Tmpo |
thymopoietin |
decreases expression |
ISO |
palbociclib results in decreased expression of TMPO mRNA |
CTD |
PMID:22869556 |
|
NCBI chr 7:25,642,752...25,667,756
Ensembl chr 7:25,586,725...25,667,727
|
|
G |
Top1 |
DNA topoisomerase I |
decreases expression |
ISO |
palbociclib results in decreased expression of TOP1 mRNA |
CTD |
PMID:24549232 |
|
NCBI chr 3:149,293,658...149,375,405
Ensembl chr 3:149,293,403...149,376,623
|
|
G |
Top2a |
DNA topoisomerase II alpha |
decreases expression multiple interactions |
ISO |
palbociclib analog results in decreased expression of TOP2A mRNA; palbociclib results in decreased expression of TOP2A mRNA; palbociclib results in decreased expression of TOP2A protein palbociclib inhibits the reaction [Doxorubicin results in increased expression of TOP2A protein]; RB1 protein affects the reaction [palbociclib inhibits the reaction [Doxorubicin results in increased expression of TOP2A protein]] |
CTD |
PMID:15542782 PMID:20948315 PMID:22751436 PMID:22869556 |
|
NCBI chr10:83,946,186...83,975,694
Ensembl chr10:83,945,735...83,976,874
|
|
G |
Tp53 |
tumor protein p53 |
decreases response to substance |
ISO |
TP53 protein mutant form results in decreased susceptibility to palbociclib |
CTD |
PMID:21278246 |
|
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
|
|
G |
Tpx2 |
TPX2, microtubule nucleation factor |
decreases expression |
ISO |
palbociclib results in decreased expression of TPX2 mRNA |
CTD |
PMID:22869556 |
|
NCBI chr 3:141,318,428...141,360,684
Ensembl chr 3:141,318,455...141,360,468
|
|
G |
Troap |
trophinin associated protein |
decreases expression |
ISO |
palbociclib results in decreased expression of TROAP mRNA |
CTD |
PMID:22869556 |
|
NCBI chr 7:130,233,534...130,242,369
Ensembl chr 7:130,234,544...130,242,365
|
|
G |
Ttc14 |
tetratricopeptide repeat domain 14 |
increases expression |
ISO |
palbociclib results in increased expression of TTC14 mRNA |
CTD |
PMID:22869556 |
|
NCBI chr 2:116,653,543...116,665,072
Ensembl chr 2:116,653,595...116,664,158
|
|
G |
Ttk |
Ttk protein kinase |
decreases expression |
ISO |
palbociclib results in decreased expression of TTK mRNA |
CTD |
PMID:22869556 |
|
NCBI chr 8:84,754,329...84,792,653
Ensembl chr 8:84,754,315...84,792,651
|
|
G |
Tubb4b |
tubulin, beta 4B class IVb |
decreases expression |
ISO |
palbociclib results in decreased expression of TUBB4B mRNA |
CTD |
PMID:22869556 |
|
NCBI chr 3:8,037,844...8,040,294
Ensembl chr 3:8,037,799...8,040,296
|
|
G |
Tubb5 |
tubulin, beta 5 class I |
decreases expression |
ISO |
palbociclib results in decreased expression of TUBB mRNA |
CTD |
PMID:22869556 |
|
NCBI chr20:2,912,779...2,916,928
Ensembl chr20:2,912,778...2,916,940
|
|
G |
Tyms |
thymidylate synthetase |
decreases expression |
ISO |
palbociclib results in decreased expression of TYMS mRNA; palbociclib results in decreased expression of TYMS protein |
CTD |
PMID:20948315 PMID:22869556 |
|
NCBI chr 9:113,313,454...113,329,551
Ensembl chr 9:113,313,452...113,329,536
|
|
G |
Ube2c |
ubiquitin-conjugating enzyme E2C |
decreases expression |
ISO |
palbociclib results in decreased expression of UBE2C mRNA |
CTD |
PMID:22869556 |
|
NCBI chr 3:153,506,636...153,509,036
Ensembl chr 3:153,506,636...153,513,339
|
|
G |
Ube2t |
ubiquitin-conjugating enzyme E2T |
decreases expression |
ISO |
palbociclib results in decreased expression of UBE2T mRNA |
CTD |
PMID:22869556 |
|
NCBI chr13:46,403,352...46,413,854
Ensembl chr13:46,403,375...46,414,835
|
|
G |
Uhrf1 |
ubiquitin-like with PHD and ring finger domains 1 |
decreases expression |
ISO |
palbociclib results in decreased expression of UHRF1 mRNA |
CTD |
PMID:22869556 |
|
NCBI chr 9:1,133,117...1,154,639
Ensembl chr 9:1,134,909...1,154,631
|
|
G |
Vim |
vimentin |
increases expression |
ISO |
palbociclib results in increased expression of VIM protein |
CTD |
PMID:22869556 |
|
NCBI chr17:76,668,701...76,677,186
Ensembl chr17:76,668,647...76,677,187
|
|
G |
Zeb1 |
zinc finger E-box binding homeobox 1 |
multiple interactions |
ISO |
palbociclib inhibits the reaction [[CDK6 protein binds to CCND3 protein] which results in increased phosphorylation of ZEB1 protein] |
CTD |
PMID:22094256 |
|
NCBI chr17:51,948,948...52,116,018
Ensembl chr17:51,948,948...52,115,214
|
|
G |
Zwint |
ZW10 interacting kinetochore protein |
decreases expression |
ISO |
palbociclib results in decreased expression of ZWINT mRNA |
CTD |
PMID:22869556 |
|
NCBI chr20:15,938,157...15,953,997
Ensembl chr20:15,938,157...15,953,957
|
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
affects abundance multiple interactions increases export increases transport affects response to substance decreases activity |
ISO EXP |
ABCB1 gene polymorphism affects the abundance of Paliperidone Palmitate; ABCB1 protein affects the abundance of Paliperidone Palmitate Cyclosporine inhibits the reaction [ABCB1A protein results in increased export of Paliperidone Palmitate] ABCB1A protein results in increased transport of Paliperidone Palmitate ABCB1A protein affects the susceptibility to Paliperidone Palmitate Paliperidone Palmitate results in decreased activity of ABCB1 protein Paliperidone Palmitate inhibits the reaction [ABCB1 protein results in decreased export of Doxorubicin] ABCB1 protein results in increased transport of Paliperidone Palmitate |
CTD |
PMID:15502009 PMID:16118767 PMID:16810505 PMID:16936711 PMID:17541883 PMID:22691713 More...
|
|
NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709
|
|
G |
Abcb1b |
ATP-binding cassette, subfamily B (MDR/TAP), member 1B |
affects response to substance |
ISO |
ABCB1B protein affects the susceptibility to Paliperidone Palmitate |
CTD |
PMID:15502009 |
|
NCBI chr 4:25,242,761...25,325,194
Ensembl chr 4:25,242,798...25,325,199
|
|
G |
Abcb4 |
ATP binding cassette subfamily B member 4 |
decreases activity |
ISO |
Paliperidone Palmitate results in decreased activity of ABCB4 protein |
CTD |
PMID:28437613 |
|
NCBI chr 4:25,150,998...25,209,489
Ensembl chr 4:25,151,953...25,209,202
|
|
G |
Abcg2 |
ATP binding cassette subfamily G member 2 |
multiple interactions |
ISO |
Paliperidone Palmitate inhibits the reaction [ABCG2 protein results in increased transport of Mitoxantrone] |
CTD |
PMID:18834354 |
|
NCBI chr 4:87,676,241...87,802,757
Ensembl chr 4:87,745,319...87,802,409
|
|
G |
Bdnf |
brain-derived neurotrophic factor |
increases expression |
EXP |
Paliperidone Palmitate results in increased expression of BDNF mRNA |
CTD |
PMID:21220416 |
|
NCBI chr 3:96,165,042...96,215,621
Ensembl chr 3:96,165,042...96,215,615
|
|
G |
Cyp2d4 |
cytochrome P450, family 2, subfamily d, polypeptide 4 |
affects abundance |
ISO |
CYP2D6 gene polymorphism affects the abundance of Paliperidone Palmitate; CYP2D6 protein affects the abundance of Paliperidone Palmitate |
CTD |
PMID:10639689 PMID:15089809 PMID:17541883 |
|
NCBI chr 7:113,882,584...113,891,754
Ensembl chr 7:113,881,618...113,891,759
|
|
G |
Drd2 |
dopamine receptor D2 |
multiple interactions affects binding |
ISO EXP |
Paliperidone Palmitate binds to and results in decreased activity of DRD2 protein Paliperidone Palmitate binds to DRD2 protein |
CTD |
PMID:19713555 PMID:22437487 |
|
NCBI chr 8:49,708,903...49,772,888
Ensembl chr 8:49,708,927...49,772,875
|
|
G |
Fads2 |
fatty acid desaturase 2 |
increases expression multiple interactions |
EXP |
Paliperidone Palmitate results in increased expression of FADS2 mRNA [Paliperidone Palmitate results in increased expression of FADS2 mRNA] which results in increased abundance of Fatty Acids, Unsaturated |
CTD |
PMID:21458237 |
|
NCBI chr 1:206,707,384...206,747,333
Ensembl chr 1:206,708,783...206,748,789
|
|
G |
Htr2a |
5-hydroxytryptamine receptor 2A |
affects binding multiple interactions |
ISO EXP |
Paliperidone Palmitate binds to HTR2A protein Paliperidone Palmitate binds to and results in decreased activity of HTR2A protein |
CTD |
PMID:7520908 PMID:19713555 PMID:22437487 |
|
NCBI chr15:49,950,035...50,022,188
Ensembl chr15:49,950,804...50,020,928
|
|
G |
Htr7 |
5-hydroxytryptamine receptor 7 |
multiple interactions |
ISO |
[Paliperidone Palmitate binds to and results in decreased activity of HTR7 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]; Paliperidone Palmitate binds to and results in decreased activity of HTR7 protein |
CTD |
PMID:18996971 PMID:19509219 PMID:20827463 |
|
NCBI chr 1:233,636,442...233,761,063
Ensembl chr 1:233,636,452...233,760,626
|
|
G |
Il1a |
interleukin 1 alpha |
increases expression |
ISO |
Paliperidone Palmitate results in increased expression of IL1A mRNA |
CTD |
PMID:32816093 |
|
NCBI chr 3:116,526,601...116,537,055
Ensembl chr 3:116,526,604...116,536,822
|
|
G |
Il1b |
interleukin 1 beta |
increases expression |
ISO |
Paliperidone Palmitate results in increased expression of IL1B mRNA |
CTD |
PMID:32816093 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il24 |
interleukin 24 |
increases expression |
ISO |
Paliperidone Palmitate results in increased expression of IL24 mRNA |
CTD |
PMID:32816093 |
|
NCBI chr13:42,353,089...42,358,487
Ensembl chr13:42,353,090...42,358,487
|
|
G |
Kcnh2 |
potassium voltage-gated channel subfamily H member 2 |
decreases activity |
ISO |
Paliperidone Palmitate results in decreased activity of KCNH2 protein |
CTD |
PMID:21394035 |
|
NCBI chr 4:10,826,834...10,859,009
Ensembl chr 4:10,826,928...10,859,008
|
|
G |
Prl |
prolactin |
increases expression |
ISO |
Paliperidone Palmitate results in increased expression of PRL protein |
CTD |
PMID:17460786 PMID:19825908 |
|
NCBI chr17:37,859,999...37,870,062
Ensembl chr17:37,860,007...37,870,062
|
|
|
G |
Fgf1 |
fibroblast growth factor 1 |
multiple interactions |
EXP |
PD 166866 inhibits the reaction [FGF1 protein results in increased abundance of Nitric Oxide]; PD 166866 inhibits the reaction [FGF1 protein results in increased expression of and results in increased secretion of NGF protein]; PD 166866 inhibits the reaction [FGF1 protein results in increased expression of FGFR1 protein]; PD 166866 inhibits the reaction [FGF1 protein results in increased expression of NOS2 mRNA]; PD 166866 inhibits the reaction [FGF1 protein results in increased expression of POSTN mRNA] |
CTD |
PMID:15121739 PMID:15773903 PMID:16524372 |
|
NCBI chr18:30,686,555...30,772,667
Ensembl chr18:30,686,581...30,772,357
|
|
G |
Fgfr1 |
Fibroblast growth factor receptor 1 |
decreases activity multiple interactions |
ISO EXP |
PD 166866 results in decreased activity of FGFR1 protein PD 166866 inhibits the reaction [FGF1 protein results in increased expression of FGFR1 protein]; PD 166866 inhibits the reaction [FGFR1 protein results in increased phosphorylation of FGFR1 protein] |
CTD |
PMID:12805413 PMID:15522930 PMID:15773903 |
|
NCBI chr16:66,492,445...66,546,731
Ensembl chr16:66,494,042...66,547,350
|
|
G |
Ngf |
nerve growth factor |
multiple interactions |
EXP |
PD 166866 inhibits the reaction [FGF1 protein results in increased expression of and results in increased secretion of NGF protein] |
CTD |
PMID:15773903 |
|
NCBI chr 2:189,901,058...189,954,452
Ensembl chr 2:189,901,058...189,954,452
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions |
EXP |
PD 166866 inhibits the reaction [FGF1 protein results in increased expression of NOS2 mRNA] |
CTD |
PMID:16524372 |
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Postn |
periostin |
multiple interactions |
EXP |
PD 166866 inhibits the reaction [FGF1 protein results in increased expression of POSTN mRNA] |
CTD |
PMID:15121739 |
|
NCBI chr 2:138,527,714...138,559,098
Ensembl chr 2:138,527,696...138,559,099
|
|
|
G |
Birc5 |
baculoviral IAP repeat-containing 5 |
multiple interactions |
ISO |
[arsenic trioxide results in increased susceptibility to PD 173074] which results in decreased expression of BIRC5 protein |
CTD |
PMID:27794399 |
|
NCBI chr10:103,072,530...103,081,382
Ensembl chr10:103,073,408...103,081,380
|
|
G |
Ccnd1 |
cyclin D1 |
multiple interactions |
ISO |
[PKI 166 co-treated with PD 173074] results in decreased expression of CCND1 protein |
CTD |
PMID:15377668 |
|
NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602
|
|
G |
Fgf1 |
fibroblast growth factor 1 |
multiple interactions |
ISO |
PD 173074 inhibits the reaction [FGF1 protein results in increased phosphorylation of FGFR4 protein] |
CTD |
PMID:15709206 |
|
NCBI chr18:30,686,555...30,772,667
Ensembl chr18:30,686,581...30,772,357
|
|
G |
Fgfr1 |
Fibroblast growth factor receptor 1 |
decreases activity decreases expression multiple interactions |
ISO |
PD 173074 results in decreased activity of FGFR1 protein PD 173074 results in decreased expression of FGFR1 protein [PD 173074 results in decreased activity of FGFR1 protein] inhibits the reaction [[Crizotinib results in decreased phosphorylation of MET protein] which results in increased expression of HGF protein]; Arsenic Trioxide promotes the reaction [PD 173074 results in decreased expression of FGFR1 protein]; PD 173074 promotes the reaction [Arsenic Trioxide results in decreased expression of FGFR1 protein] |
CTD |
PMID:22683780 PMID:27794399 |
|
NCBI chr16:66,492,445...66,546,731
Ensembl chr16:66,494,042...66,547,350
|
|
G |
Fgfr3 |
fibroblast growth factor receptor 3 |
decreases activity |
ISO |
PD 173074 results in decreased activity of FGFR3 protein |
CTD |
PMID:15029211 |
|
NCBI chr14:76,987,242...77,002,671
Ensembl chr14:76,987,993...77,003,341
|
|
G |
Fgfr4 |
fibroblast growth factor receptor 4 |
multiple interactions decreases activity |
ISO |
PD 173074 inhibits the reaction [FGF1 protein results in increased phosphorylation of FGFR4 protein] PD 173074 results in decreased activity of FGFR4 protein |
CTD |
PMID:15377668 PMID:15709206 |
|
NCBI chr17:9,461,541...9,476,268
Ensembl chr17:9,461,547...9,476,242
|
|
G |
Hgf |
hepatocyte growth factor |
multiple interactions |
ISO |
[PD 173074 results in decreased activity of FGFR1 protein] inhibits the reaction [[crizotinib results in decreased phosphorylation of MET protein] which results in increased expression of HGF protein] |
CTD |
PMID:22683780 |
|
NCBI chr 4:18,673,736...18,745,582
Ensembl chr 4:18,677,101...18,745,409
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
decreases phosphorylation decreases expression multiple interactions |
ISO |
PD 173074 results in decreased phosphorylation of MAPK1 protein PD 173074 results in decreased expression of MAPK1 protein PD 173074 inhibits the reaction [PHLPP1 gene mutant form results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:15029211 PMID:25953896 PMID:27794399 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
decreases phosphorylation decreases expression multiple interactions |
ISO |
PD 173074 results in decreased phosphorylation of MAPK3 protein PD 173074 results in decreased expression of MAPK3 protein PD 173074 inhibits the reaction [PHLPP1 gene mutant form results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:15029211 PMID:25953896 PMID:27794399 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Met |
MET proto-oncogene, receptor tyrosine kinase |
multiple interactions |
ISO |
[PD 173074 results in decreased activity of FGFR1 protein] inhibits the reaction [[crizotinib results in decreased phosphorylation of MET protein] which results in increased expression of HGF protein] |
CTD |
PMID:22683780 |
|
NCBI chr 4:45,790,456...45,898,139
Ensembl chr 4:45,790,791...45,897,876
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
multiple interactions |
ISO |
[arsenic trioxide co-treated with PD 173074] results in increased expression of PARP1 protein modified form; [arsenic trioxide results in increased susceptibility to PD 173074] which results in increased expression of PARP1 protein modified form; [PD 173074 results in increased susceptibility to arsenic trioxide] which results in increased expression of PARP1 protein modified form |
CTD |
PMID:27794399 |
|
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Phlpp1 |
PH domain and leucine rich repeat protein phosphatase 1 |
multiple interactions |
ISO |
PD 173074 inhibits the reaction [PHLPP1 gene mutant form results in increased phosphorylation of MAPK1 protein]; PD 173074 inhibits the reaction [PHLPP1 gene mutant form results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:25953896 |
|
NCBI chr13:22,308,532...22,530,978
Ensembl chr13:22,308,548...22,530,977
|
|
G |
Raf1 |
Raf-1 proto-oncogene, serine/threonine kinase |
decreases expression multiple interactions |
ISO |
PD 173074 results in decreased expression of RAF1 protein; PD 173074 results in decreased expression of RAF1 protein modified form [arsenic trioxide co-treated with PD 173074] results in decreased expression of RAF1 protein; [arsenic trioxide co-treated with PD 173074] results in decreased expression of RAF1 protein modified form; [arsenic trioxide results in increased susceptibility to PD 173074] which results in decreased expression of RAF1 protein; [PD 173074 results in increased susceptibility to arsenic trioxide] which results in decreased expression of RAF1 protein; [PD 173074 results in increased susceptibility to arsenic trioxide] which results in decreased expression of RAF1 protein modified form; arsenic trioxide promotes the reaction [PD 173074 results in decreased expression of RAF1 protein modified form]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [[arsenic trioxide co-treated with PD 173074] results in decreased expression of RAF1 protein modified form]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [[arsenic trioxide co-treated with PD 173074] results in decreased expression of RAF1 protein] |
CTD |
PMID:27794399 |
|
NCBI chr 4:148,679,534...148,740,265
Ensembl chr 4:148,679,530...148,740,317
|
|
G |
Rps6kb1 |
ribosomal protein S6 kinase B1 |
multiple interactions |
ISO |
[PKI 166 co-treated with PD 173074] results in decreased activity of RPS6KB1 protein |
CTD |
PMID:15377668 |
|
NCBI chr10:71,323,777...71,367,908
Ensembl chr10:71,323,777...71,367,908
|
|
G |
Src |
SRC proto-oncogene, non-receptor tyrosine kinase |
multiple interactions decreases expression |
ISO |
[Arsenic Trioxide co-treated with PD 173074] results in decreased expression of SRC protein; [Arsenic Trioxide results in increased susceptibility to PD 173074] which results in decreased expression of SRC protein; [PD 173074 results in increased susceptibility to Arsenic Trioxide] which results in decreased expression of SRC protein; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [[Arsenic Trioxide co-treated with PD 173074] results in decreased expression of SRC protein]; PD 173074 promotes the reaction [Arsenic Trioxide results in decreased expression of SRC protein modified form]; PD 173074 promotes the reaction [Arsenic Trioxide results in decreased expression of SRC protein] PD 173074 results in decreased expression of SRC protein; PD 173074 results in decreased expression of SRC protein modified form |
CTD |
PMID:27794399 |
|
NCBI chr 3:146,091,969...146,139,492
Ensembl chr 3:146,091,841...146,139,476
|
|
G |
Tbx3 |
T-box transcription factor 3 |
multiple interactions |
ISO |
PD 173074 inhibits the reaction [afimoxifene results in increased expression of TBX3 protein]; PD 173074 inhibits the reaction [Estrogens results in increased expression of TBX3 protein] |
CTD |
PMID:21098263 |
|
NCBI chr12:36,879,924...36,894,849
Ensembl chr12:36,881,445...36,893,708
|
|
G |
Vegfa |
vascular endothelial growth factor A |
multiple interactions |
ISO |
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide promotes the reaction [PD 173074 inhibits the reaction [Sodium Chloride results in increased expression of VEGFA mRNA]]; PD 173074 inhibits the reaction [Sodium Chloride results in increased expression of VEGFA mRNA] |
CTD |
PMID:26800359 |
|
NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641
|
|
|
G |
Calca |
calcitonin-related polypeptide alpha |
multiple interactions |
EXP |
pemirolast inhibits the reaction [Paclitaxel results in increased expression of CALCA protein] |
CTD |
PMID:15033348 |
|
NCBI chr 1:168,878,212...168,883,176
Ensembl chr 1:168,878,214...168,883,105
|
|
G |
Tac1 |
tachykinin, precursor 1 |
multiple interactions decreases secretion |
EXP |
pemirolast inhibits the reaction [Paclitaxel results in increased expression of TAC1 protein]; pemirolast inhibits the reaction [Paclitaxel results in increased secretion of TAC1 protein alternative form] pemirolast results in decreased secretion of TAC1 protein |
CTD |
PMID:15033348 PMID:21233199 PMID:21539837 |
|
NCBI chr 4:35,679,183...35,687,180
Ensembl chr 4:35,679,704...35,687,178
|
|
|
G |
Abcc4 |
ATP binding cassette subfamily C member 4 |
increases transport |
ISO |
ABCC4 protein results in increased transport of Pipemidic Acid |
CTD |
PMID:17939016 |
|
NCBI chr15:95,541,186...95,774,898
Ensembl chr15:95,542,315...95,774,283
|
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
affects abundance multiple interactions increases export increases transport decreases activity affects response to substance increases response to substance |
ISO EXP |
ABCB1 gene polymorphism affects the abundance of Risperidone; ABCB1 protein affects the abundance of Risperidone Cyclosporine inhibits the reaction [ABCB1A protein results in increased export of Risperidone] ABCB1A protein results in increased transport of Risperidone Risperidone results in decreased activity of ABCB1 protein ABCB1A protein affects the susceptibility to Risperidone ABCB1 protein results in increased transport of Risperidone Risperidone inhibits the reaction [ABCB1 protein results in decreased export of Doxorubicin] ABCB1 protein results in increased susceptibility to Risperidone ABCB1 gene polymorphism affects the susceptibility to Risperidone; ABCB1 protein affects the susceptibility to Risperidone |
CTD |
PMID:15502009 PMID:16118767 PMID:16810505 PMID:16936711 PMID:17054409 PMID:17541883 PMID:18708991 PMID:19997080 PMID:20563569 PMID:21449914 PMID:22623266 PMID:22691713 More...
|
|
NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709
|
|
G |
Abcb1b |
ATP-binding cassette, subfamily B (MDR/TAP), member 1B |
affects response to substance |
ISO |
ABCB1B protein affects the susceptibility to Risperidone |
CTD |
PMID:15502009 |
|
NCBI chr 4:25,242,761...25,325,194
Ensembl chr 4:25,242,798...25,325,199
|
|
G |
Abcg2 |
ATP binding cassette subfamily G member 2 |
multiple interactions |
ISO |
Risperidone inhibits the reaction [ABCG2 protein results in increased transport of Mitoxantrone]; Risperidone inhibits the reaction [ABCG2 protein results in increased uptake of estrone sulfate] |
CTD |
PMID:18834354 |
|
NCBI chr 4:87,676,241...87,802,757
Ensembl chr 4:87,745,319...87,802,409
|
|
G |
Adipoq |
adiponectin, C1Q and collagen domain containing |
multiple interactions increases expression |
ISO |
Berberine inhibits the reaction [Risperidone results in increased expression of ADIPOQ mRNA] |
CTD |
PMID:20564506 |
|
NCBI chr11:77,721,912...77,735,644
Ensembl chr11:77,721,912...77,735,564
|
|
G |
Bdnf |
brain-derived neurotrophic factor |
decreases expression multiple interactions |
EXP ISO |
Risperidone results in decreased expression of BDNF mRNA BDNF gene polymorphism affects the reaction [Risperidone results in increased expression of PRL protein] Risperidone inhibits the reaction [Rotenone results in decreased expression of BDNF mRNA] |
CTD |
PMID:12393228 PMID:17442543 PMID:19997080 |
|
NCBI chr 3:96,165,042...96,215,621
Ensembl chr 3:96,165,042...96,215,615
|
|
G |
Calm2 |
calmodulin 2 |
increases expression |
EXP |
Risperidone results in increased expression of CALM2 mRNA |
CTD |
PMID:19289156 |
|
NCBI chr 6:7,091,624...7,104,284
Ensembl chr 6:7,091,567...7,104,287
|
|
G |
Camk2a |
calcium/calmodulin-dependent protein kinase II alpha |
decreases expression |
EXP |
Risperidone results in decreased expression of CAMK2A protein |
CTD |
PMID:19289156 |
|
NCBI chr18:54,378,642...54,441,120
Ensembl chr18:54,378,784...54,438,994
|
|
G |
Camk4 |
calcium/calmodulin-dependent protein kinase IV |
decreases expression |
EXP |
Risperidone results in decreased expression of CAMK4 protein |
CTD |
PMID:19289156 |
|
NCBI chr18:24,582,988...24,811,918
Ensembl chr18:24,585,269...24,802,487
|
|
G |
Camkk1 |
calcium/calmodulin-dependent protein kinase kinase 1 |
decreases expression |
EXP |
Risperidone results in decreased expression of CAMKK1 protein |
CTD |
PMID:19289156 |
|
NCBI chr10:57,637,335...57,660,498
Ensembl chr10:57,637,391...57,660,498
|
|
G |
Camkk2 |
calcium/calmodulin-dependent protein kinase kinase 2 |
decreases expression |
EXP |
Risperidone results in decreased expression of CAMKK2 protein |
CTD |
PMID:19289156 |
|
NCBI chr12:33,791,023...33,845,000
Ensembl chr12:33,791,052...33,843,279
|
|
G |
Casp3 |
caspase 3 |
multiple interactions increases activity |
ISO |
Palmitic Acid promotes the reaction [Risperidone results in increased activity of CASP3 protein] |
CTD |
PMID:22700542 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp7 |
caspase 7 |
multiple interactions increases activity |
ISO |
Palmitic Acid promotes the reaction [Risperidone results in increased activity of CASP7 protein] |
CTD |
PMID:22700542 |
|
NCBI chr 1:255,437,195...255,476,737
Ensembl chr 1:255,437,172...255,476,729
|
|
G |
Cebpa |
CCAAT/enhancer binding protein alpha |
multiple interactions increases expression |
ISO |
Berberine inhibits the reaction [Risperidone results in increased expression of CEBPA mRNA]; Berberine inhibits the reaction [Risperidone results in increased expression of CEBPA protein] Risperidone results in increased expression of CEBPA mRNA; Risperidone results in increased expression of CEBPA protein |
CTD |
PMID:20564506 |
|
NCBI chr 1:87,759,631...87,762,303
Ensembl chr 1:87,759,433...87,762,412
|
|
G |
Chrm4 |
cholinergic receptor, muscarinic 4 |
affects response to substance |
ISO |
CHRM4 affects the susceptibility to Risperidone |
CTD |
PMID:21269601 |
|
NCBI chr 3:77,893,425...77,901,166
Ensembl chr 3:77,893,425...77,901,159
|
|
G |
Comt |
catechol-O-methyltransferase |
increases expression |
EXP |
Risperidone results in increased expression of COMT mRNA |
CTD |
PMID:15964593 |
|
NCBI chr11:82,568,052...82,587,642
Ensembl chr11:82,568,025...82,587,642
|
|
G |
Crh |
corticotropin releasing hormone |
decreases expression |
ISO |
Risperidone results in decreased expression of CRH mRNA |
CTD |
PMID:16205782 |
|
NCBI chr 2:102,143,055...102,144,919
Ensembl chr 2:102,143,055...102,144,919
|
|
G |
Ctnnb1 |
catenin beta 1 |
multiple interactions increases expression |
EXP |
DRD2 protein affects the reaction [Risperidone results in increased expression of CTNNB1 protein] |
CTD |
PMID:16144542 |
|
NCBI chr 8:120,640,008...120,667,110
Ensembl chr 8:120,639,995...120,667,111
|
|
G |
Cyp2d4 |
cytochrome P450, family 2, subfamily d, polypeptide 4 |
affects metabolic processing increases metabolic processing increases response to substance affects response to substance decreases hydroxylation decreases metabolic processing affects abundance multiple interactions |
ISO |
CYP2D6 gene polymorphism affects the metabolism of Risperidone; CYP2D6 protein affects the metabolism of Risperidone CYP2D6 protein results in increased metabolism of Risperidone CYP2D6 protein results in increased susceptibility to Risperidone CYP2D6 gene polymorphism affects the susceptibility to Risperidone; CYP2D6 protein polymorphism affects the susceptibility to Risperidone CYP2D6 gene polymorphism results in decreased hydroxylation of Risperidone CYP2D6 gene polymorphism results in decreased metabolism of Risperidone CYP2D6 gene polymorphism affects the abundance of Risperidone; CYP2D6 protein affects the abundance of Risperidone CYP2D6 gene polymorphism affects the metabolism of and affects the abundance of Risperidone; CYP2D6 protein affects the metabolism of and affects the abundance of Risperidone |
CTD |
PMID:10639689 PMID:15089809 PMID:15260906 PMID:15565299 PMID:15669884 PMID:16044105 PMID:17224713 PMID:17541883 PMID:18708991 PMID:19387994 PMID:20332423 PMID:20563569 PMID:21449914 PMID:22623266 PMID:22745940 PMID:23609392 More...
|
|
NCBI chr 7:113,882,584...113,891,754
Ensembl chr 7:113,881,618...113,891,759
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
multiple interactions affects response to substance |
ISO |
N-Methyl-3,4-methylenedioxyamphetamine inhibits the reaction [Risperidone promotes the reaction [NR1I2 protein results in increased expression of CYP3A4 mRNA]]; Risperidone promotes the reaction [NR1I2 protein results in increased expression of CYP3A4 mRNA] CYP3A4 gene polymorphism affects the susceptibility to Risperidone; CYP3A4 protein affects the susceptibility to Risperidone |
CTD |
PMID:19395426 PMID:21402137 |
|
NCBI chr12:9,207,986...9,230,038
Ensembl chr12:9,015,383...9,285,008
|
|
G |
Cyp3a9 |
cytochrome P450, family 3, subfamily a, polypeptide 9 |
affects abundance increases metabolic processing |
ISO |
CYP3A5 gene polymorphism affects the abundance of Risperidone; CYP3A5 protein affects the abundance of Risperidone CYP3A5 protein results in increased metabolism of Risperidone |
CTD |
PMID:18708991 PMID:20332423 |
|
NCBI chr12:16,806,222...16,846,428
Ensembl chr12:16,806,207...16,846,422
|
|
G |
Drd2 |
dopamine receptor D2 |
multiple interactions affects binding increases response to substance affects response to substance |
ISO EXP |
Risperidone binds to and results in decreased activity of DRD2 protein Risperidone binds to DRD2 protein [Risperidone binds to and results in decreased activity of DRD2 protein] which results in increased expression of PPP3CA protein; DRD2 protein affects the reaction [Risperidone results in increased expression of CTNNB1 protein]; DRD2 protein affects the reaction [Risperidone results in increased expression of DVL3 protein]; DRD2 protein affects the reaction [Risperidone results in increased expression of GSK3A protein]; DRD2 protein affects the reaction [Risperidone results in increased expression of GSK3B protein]; Risperidone binds to and results in decreased activity of DRD2 protein; Risperidone inhibits the reaction [Apomorphine binds to and results in increased activity of DRD2 protein]; Risperidone promotes the reaction [Dopamine binds to DRD2 protein] DRD2 gene polymorphism results in increased susceptibility to Risperidone; DRD2 gene SNP results in increased susceptibility to Risperidone; DRD2 protein results in increased susceptibility to Risperidone DRD2 gene polymorphism affects the susceptibility to Risperidone |
CTD |
PMID:1380082 PMID:7520908 PMID:8804920 PMID:10831489 PMID:12191584 PMID:15710053 PMID:15716360 PMID:16033416 PMID:16144542 PMID:16513859 PMID:18058087 PMID:19339912 PMID:19640686 PMID:19910723 PMID:20361897 PMID:20375926 PMID:21869689 PMID:22437487 PMID:22967779 More...
|
|
NCBI chr 8:49,708,903...49,772,888
Ensembl chr 8:49,708,927...49,772,875
|
|
G |
Drd3 |
dopamine receptor D3 |
increases response to substance |
ISO |
DRD3 gene SNP results in increased susceptibility to Risperidone; DRD3 protein results in increased susceptibility to Risperidone |
CTD |
PMID:19506579 PMID:19997080 |
|
NCBI chr11:56,879,689...56,931,901
Ensembl chr11:56,879,689...56,940,596
|
|
G |
Dvl3 |
dishevelled segment polarity protein 3 |
multiple interactions increases expression |
EXP |
DRD2 protein affects the reaction [Risperidone results in increased expression of DVL3 protein] |
CTD |
PMID:16144542 |
|
NCBI chr11:80,365,446...80,382,641
Ensembl chr11:80,366,117...80,382,462
|
|
G |
Egr1 |
early growth response 1 |
decreases expression |
EXP |
Risperidone results in decreased expression of EGR1 protein |
CTD |
PMID:17028028 |
|
NCBI chr18:26,463,333...26,465,531
Ensembl chr18:26,462,981...26,466,766
|
|
G |
Egr2 |
early growth response 2 |
decreases expression multiple interactions |
EXP ISO |
Risperidone results in decreased expression of EGR2 protein Risperidone inhibits the reaction [Toluene promotes the reaction [4-iodo-2,5-dimethoxyphenylisopropylamine results in increased expression of EGR2 protein]] |
CTD |
PMID:17028028 PMID:32980479 |
|
NCBI chr20:21,051,270...21,056,322
Ensembl chr20:21,051,277...21,055,562
|
|
G |
Erbb2 |
erb-b2 receptor tyrosine kinase 2 |
increases phosphorylation |
EXP |
Risperidone results in increased phosphorylation of ERBB2 protein |
CTD |
PMID:26961615 |
|
NCBI chr10:83,411,197...83,435,078
Ensembl chr10:83,411,313...83,435,078
|
|
G |
Erbb4 |
erb-b2 receptor tyrosine kinase 4 |
multiple interactions |
EXP |
Risperidone results in increased expression of and results in increased phosphorylation of ERBB4 protein |
CTD |
PMID:26961615 |
|
NCBI chr 9:69,523,733...70,596,743
Ensembl chr 9:69,531,481...70,596,595
|
|
G |
Fads2 |
fatty acid desaturase 2 |
increases expression multiple interactions |
EXP |
Risperidone results in increased expression of FADS2 mRNA [Risperidone results in increased expression of FADS2 mRNA] which results in increased abundance of Fatty Acids, Unsaturated |
CTD |
PMID:21458237 |
|
NCBI chr 1:206,707,384...206,747,333
Ensembl chr 1:206,708,783...206,748,789
|
|
G |
Fas |
Fas cell surface death receptor |
multiple interactions increases expression |
ISO |
Berberine inhibits the reaction [Risperidone results in increased expression of FAS mRNA] |
CTD |
PMID:20564506 |
|
NCBI chr 1:231,798,963...231,832,591
Ensembl chr 1:231,798,960...231,832,591
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
multiple interactions increases expression |
EXP ISO |
Risperidone promotes the reaction [Rotenone results in increased expression of FOS mRNA] Dronabinol inhibits the reaction [Risperidone results in increased expression of FOS protein]; Risperidone inhibits the reaction [Toluene promotes the reaction [4-iodo-2,5-dimethoxyphenylisopropylamine results in increased expression of FOS protein]] Risperidone results in increased expression of FOS mRNA |
CTD |
PMID:11516571 PMID:17442543 PMID:28272498 PMID:32980479 |
|
NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036
|
|
G |
Fshb |
follicle stimulating hormone subunit beta |
affects expression |
ISO |
Risperidone affects the expression of FSHB protein |
CTD |
PMID:18838228 |
|
NCBI chr 3:93,548,560...93,552,370
Ensembl chr 3:93,548,560...93,552,370
|
|
G |
Gsk3a |
glycogen synthase kinase 3 alpha |
increases expression multiple interactions |
EXP |
Risperidone results in increased expression of GSK3A protein DRD2 protein affects the reaction [Risperidone results in increased expression of GSK3A protein] |
CTD |
PMID:16144542 |
|
NCBI chr 1:80,815,843...80,825,732
Ensembl chr 1:80,815,850...80,825,802
|
|
G |
Gsk3b |
glycogen synthase kinase 3 beta |
multiple interactions increases expression |
EXP |
DRD2 protein affects the reaction [Risperidone results in increased expression of GSK3B protein] |
CTD |
PMID:16144542 |
|
NCBI chr11:62,498,997...62,648,665
Ensembl chr11:62,504,316...62,648,646
|
|
G |
Hmgcr |
3-hydroxy-3-methylglutaryl-CoA reductase |
increases expression |
ISO |
Risperidone results in increased expression of HMGCR mRNA |
CTD |
PMID:17052361 |
|
NCBI chr 2:27,997,523...28,018,983
Ensembl chr 2:27,997,525...28,019,703
|
|
G |
Homer1 |
homer scaffold protein 1 |
increases expression |
EXP |
Risperidone results in increased expression of HOMER1 mRNA |
CTD |
PMID:20147574 |
|
NCBI chr 2:24,542,777...24,645,715
Ensembl chr 2:24,543,093...24,644,785
|
|
G |
Htr1a |
5-hydroxytryptamine receptor 1A |
increases response to substance multiple interactions |
EXP |
HTR1A protein results in increased susceptibility to Risperidone N-(2-(4-(2-methoxyphenyl)-1-piperazinyl)ethyl)-N-(2-pyridinyl)cyclohexanecarboxamide inhibits the reaction [HTR1A protein results in increased susceptibility to Risperidone] |
CTD |
PMID:17530476 |
|
NCBI chr 2:36,694,174...36,695,442
Ensembl chr 2:36,694,174...36,695,442
|
|
G |
Htr2a |
5-hydroxytryptamine receptor 2A |
increases response to substance affects binding multiple interactions affects response to substance |
ISO EXP |
HTR2A gene SNP results in increased susceptibility to Risperidone; HTR2A protein results in increased susceptibility to Risperidone Risperidone binds to HTR2A protein Risperidone binds to and results in decreased activity of HTR2A protein; Risperidone inhibits the reaction [Ketanserin binds to HTR2A protein] HTR2A gene polymorphism affects the reaction [Risperidone results in increased expression of PRL protein]; Risperidone binds to and results in decreased activity of HTR2A protein HTR2A protein affects the susceptibility to Risperidone |
CTD |
PMID:7520908 PMID:11927170 PMID:12191584 PMID:16314884 PMID:16948927 PMID:19997080 PMID:22437487 More...
|
|
NCBI chr15:49,950,035...50,022,188
Ensembl chr15:49,950,804...50,020,928
|
|
G |
Htr2c |
5-hydroxytryptamine receptor 2C |
affects response to substance multiple interactions increases response to substance |
ISO |
HTR2C gene polymorphism affects the susceptibility to Risperidone; HTR2C protein affects the susceptibility to Risperidone HTR2C gene polymorphism affects the reaction [Risperidone results in increased expression of PRL protein] HTR2C protein results in increased susceptibility to Risperidone |
CTD |
PMID:19142101 PMID:19997080 |
|
NCBI chr X:110,640,777...110,870,288
Ensembl chr X:110,641,153...110,870,287
|
|
G |
Htr6 |
5-hydroxytryptamine receptor 6 |
multiple interactions |
ISO |
HTR6 gene polymorphism affects the reaction [Risperidone results in increased expression of PRL protein] |
CTD |
PMID:19997080 |
|
NCBI chr 5:151,295,269...151,312,853
Ensembl chr 5:151,296,662...151,311,912
|
|
G |
Htr7 |
5-hydroxytryptamine receptor 7 |
multiple interactions |
ISO |
2-((2-(dimethylamino)ethyl)thio)-3-phenylquinoline inhibits the reaction [Risperidone binds to and results in decreased activity of HTR7 protein]; [Risperidone binds to and results in decreased activity of HTR7 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]; Clozapine inhibits the reaction [Risperidone binds to and results in decreased activity of HTR7 protein]; Cyproheptadine inhibits the reaction [Risperidone binds to and results in decreased activity of HTR7 protein]; mesulergine inhibits the reaction [Risperidone binds to and results in decreased activity of HTR7 protein]; Mianserin inhibits the reaction [Risperidone binds to and results in decreased activity of HTR7 protein]; Risperidone binds to and results in decreased activity of HTR7 protein; SB 269970 inhibits the reaction [Risperidone binds to and results in decreased activity of HTR7 protein] |
CTD |
PMID:18996971 PMID:19509219 PMID:20827463 |
|
NCBI chr 1:233,636,442...233,761,063
Ensembl chr 1:233,636,452...233,760,626
|
|
G |
Inha |
inhibin subunit alpha |
multiple interactions |
ISO |
Risperidone results in increased expression of [INHA protein binds to INHBB protein] |
CTD |
PMID:18838228 |
|
NCBI chr 9:76,994,465...76,997,366
Ensembl chr 9:76,993,589...76,997,248
|
|
G |
Inhbb |
inhibin subunit beta B |
multiple interactions |
ISO |
Risperidone results in increased expression of [INHA protein binds to INHBB protein] |
CTD |
PMID:18838228 |
|
NCBI chr13:30,530,860...30,536,566
Ensembl chr13:30,530,860...30,537,832
|
|
G |
Ins2 |
insulin 2 |
increases expression |
ISO |
Risperidone results in increased expression of INS protein |
CTD |
PMID:11927762 PMID:16601995 |
|
NCBI chr 1:197,843,277...197,992,522
Ensembl chr 1:197,843,281...197,864,775
|
|
G |
Kcnh2 |
potassium voltage-gated channel subfamily H member 2 |
multiple interactions |
ISO |
Risperidone inhibits the reaction [KCNH2 protein results in increased transport of Thallium] |
CTD |
PMID:21158687 |
|
NCBI chr 4:10,826,834...10,859,009
Ensembl chr 4:10,826,928...10,859,008
|
|
G |
Ldlr |
low density lipoprotein receptor |
multiple interactions increases expression |
ISO |
Berberine inhibits the reaction [Risperidone results in increased expression of LDLR mRNA] |
CTD |
PMID:20564506 |
|
NCBI chr 8:20,270,020...20,292,981
Ensembl chr 8:20,270,041...20,294,580
|
|
G |
Maoa |
monoamine oxidase A |
affects response to substance increases response to substance |
ISO |
MAOA gene polymorphism affects the susceptibility to Risperidone MAOA protein results in increased susceptibility to Risperidone |
CTD |
PMID:22544010 |
|
NCBI chr X:6,032,172...6,098,308
Ensembl chr X:6,030,795...6,099,593
|
|
G |
Maob |
monoamine oxidase B |
increases expression |
EXP |
Risperidone results in increased expression of MAOB mRNA |
CTD |
PMID:15964593 |
|
NCBI chr X:5,907,327...6,010,996
Ensembl chr X:5,907,266...6,011,003
|
|
G |
Map2 |
microtubule-associated protein 2 |
increases expression |
EXP |
Risperidone results in increased expression of MAP2 mRNA |
CTD |
PMID:15079866 |
|
NCBI chr 9:67,723,422...67,981,886
Ensembl chr 9:67,723,371...67,979,809
|
|
G |
Ngfr |
nerve growth factor receptor |
decreases expression |
EXP |
Risperidone results in decreased expression of NGFR mRNA |
CTD |
PMID:12111809 PMID:16513140 |
|
NCBI chr10:80,515,287...80,533,518
Ensembl chr10:80,515,299...80,533,518
|
|
G |
Nr1i2 |
nuclear receptor subfamily 1, group I, member 2 |
multiple interactions |
ISO |
N-Methyl-3,4-methylenedioxyamphetamine inhibits the reaction [Risperidone promotes the reaction [NR1I2 protein results in increased expression of CYP3A4 mRNA]]; Risperidone promotes the reaction [NR1I2 protein results in increased expression of CYP3A4 mRNA] |
CTD |
PMID:21402137 |
|
NCBI chr11:62,460,213...62,496,665
Ensembl chr11:62,460,213...62,496,658
|
|
G |
Nrg1 |
neuregulin 1 |
increases expression |
EXP |
Risperidone results in increased expression of NRG1 protein |
CTD |
PMID:26961615 |
|
NCBI chr16:59,250,658...60,303,024
Ensembl chr16:59,250,854...60,296,884
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
increases expression multiple interactions |
ISO |
Risperidone results in increased expression of PPARG mRNA; Risperidone results in increased expression of PPARG protein Berberine inhibits the reaction [Risperidone results in increased expression of PPARG mRNA]; Berberine inhibits the reaction [Risperidone results in increased expression of PPARG protein] |
CTD |
PMID:20564506 |
|
NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
|
|
G |
Ppp3ca |
protein phosphatase 3 catalytic subunit alpha |
multiple interactions decreases expression |
EXP |
[Risperidone binds to and results in decreased activity of DRD2 protein] which results in increased expression of PPP3CA protein Risperidone results in decreased expression of PPP3CA mRNA; Risperidone results in decreased expression of PPP3CA protein |
CTD |
PMID:16033416 |
|
NCBI chr 2:225,165,981...225,440,978
Ensembl chr 2:225,165,766...225,438,974
|
|
G |
Prl |
prolactin |
multiple interactions increases secretion increases expression |
ISO EXP |
[Risperidone co-treated with Clozapine] results in increased expression of PRL protein; Aripiprazole inhibits the reaction [Risperidone results in increased secretion of PRL protein]; BDNF gene polymorphism affects the reaction [Risperidone results in increased expression of PRL protein]; HTR2A gene polymorphism affects the reaction [Risperidone results in increased expression of PRL protein]; HTR2C gene polymorphism affects the reaction [Risperidone results in increased expression of PRL protein]; HTR6 gene polymorphism affects the reaction [Risperidone results in increased expression of PRL protein] Risperidone inhibits the reaction [Dopamine results in decreased secretion of PRL protein] |
CTD |
PMID:1380082 PMID:9696519 PMID:9989566 PMID:10084644 PMID:11048906 PMID:11155212 PMID:11561931 PMID:11927762 PMID:12902212 PMID:12974991 PMID:15206663 PMID:15286066 PMID:15289996 PMID:15669890 PMID:15960571 PMID:16379509 PMID:16730335 PMID:17224713 PMID:18063941 PMID:18080171 PMID:18466271 PMID:18562423 PMID:18759643 PMID:18838228 PMID:19653986 PMID:19825908 PMID:19906340 PMID:19997080 PMID:20373475 PMID:20661022 PMID:20814333 More...
|
|
NCBI chr17:37,859,999...37,870,062
Ensembl chr17:37,860,007...37,870,062
|
|
G |
Rgs2 |
regulator of G-protein signaling 2 |
increases expression |
EXP |
Risperidone results in increased expression of RGS2 mRNA |
CTD |
PMID:11516571 |
|
NCBI chr13:55,799,749...55,802,354
Ensembl chr13:55,798,829...55,802,385
|
|
G |
S100b |
S100 calcium binding protein B |
increases secretion |
EXP |
Risperidone results in increased secretion of S100B protein |
CTD |
PMID:18421423 |
|
NCBI chr20:12,372,866...12,381,619
Ensembl chr20:12,372,881...12,394,743
|
|
G |
Slc17a6 |
solute carrier family 17 member 6 |
increases expression |
ISO |
Risperidone results in increased expression of SLC17A6 mRNA; Risperidone results in increased expression of SLC17A6 protein |
CTD |
PMID:18155072 |
|
NCBI chr 1:101,212,489...101,252,543
Ensembl chr 1:101,212,489...101,252,542
|
|
G |
Snap25 |
synaptosome associated protein 25 |
affects response to substance |
ISO |
SNAP25 gene SNP affects the susceptibility to Risperidone |
CTD |
PMID:15823421 |
|
NCBI chr 3:124,041,898...124,123,761
Ensembl chr 3:124,041,898...124,123,760
|
|
G |
Sod1 |
superoxide dismutase 1 |
multiple interactions increases expression |
EXP |
Risperidone inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of SOD1 mRNA]; Risperidone inhibits the reaction [Haloperidol results in decreased expression of SOD1 protein] Risperidone results in increased expression of SOD1 mRNA |
CTD |
PMID:12111809 PMID:12752374 PMID:16564057 |
|
NCBI chr11:29,456,673...29,462,249
Ensembl chr11:29,456,558...29,462,249
|
|
G |
Srebf1 |
sterol regulatory element binding transcription factor 1 |
multiple interactions increases expression |
ISO |
Berberine inhibits the reaction [Risperidone results in increased expression of SREBF1 mRNA]; Berberine inhibits the reaction [Risperidone results in increased expression of SREBF1 protein] Risperidone results in increased expression of SREBF1 mRNA; Risperidone results in increased expression of SREBF1 protein |
CTD |
PMID:20564506 |
|
NCBI chr10:45,007,637...45,029,650
Ensembl chr10:45,007,637...45,029,650
|
|
G |
Stat3 |
signal transducer and activator of transcription 3 |
multiple interactions |
EXP |
Risperidone inhibits the reaction [Rotenone results in decreased expression of STAT3 mRNA] |
CTD |
PMID:17442543 |
|
NCBI chr10:85,811,206...85,863,057
Ensembl chr10:85,811,218...85,863,057
|
|
G |
Th |
tyrosine hydroxylase |
increases expression |
EXP |
Risperidone results in increased expression of TH protein |
CTD |
PMID:17028028 |
|
NCBI chr 1:198,071,500...198,078,832
Ensembl chr 1:198,071,503...198,109,767
|
|
|
G |
Acaca |
acetyl-CoA carboxylase alpha |
multiple interactions |
ISO |
trametinib affects the reaction [[BRAF protein affects the susceptibility to Vemurafenib] which affects the expression of ACACA mRNA] |
CTD |
PMID:29950559 |
|
NCBI chr10:69,014,261...69,276,453
Ensembl chr10:69,014,170...69,276,457
|
|
G |
Acly |
ATP citrate lyase |
multiple interactions |
ISO |
trametinib affects the reaction [[BRAF protein affects the susceptibility to Vemurafenib] which affects the expression of ACLY mRNA] |
CTD |
PMID:29950559 |
|
NCBI chr10:85,412,045...85,464,253
Ensembl chr10:85,412,049...85,463,320
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
increases phosphorylation multiple interactions |
ISO |
trametinib results in increased phosphorylation of AKT1 protein [omipalisib co-treated with trametinib] results in decreased phosphorylation of AKT1 protein |
CTD |
PMID:22733540 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Appl1 |
adaptor protein, phosphotyrosine interacting with PH domain and leucine zipper 1 |
multiple interactions |
ISO |
trametinib inhibits the reaction [Poly I-C results in increased degradation of APPL1 protein] |
CTD |
PMID:25780039 |
|
NCBI chr16:2,118,503...2,166,741
Ensembl chr16:2,121,255...2,166,692
|
|
G |
Bcl2l11 |
Bcl2-like 11 |
multiple interactions increases expression |
ISO |
[trametinib co-treated with omipalisib] results in increased expression of BCL2L11 protein trametinib results in increased expression of BCL2L11 protein |
CTD |
PMID:22733540 |
|
NCBI chr 3:115,366,783...115,404,068
Ensembl chr 3:115,366,646...115,404,068
|
|
G |
Braf |
B-Raf proto-oncogene, serine/threonine kinase |
multiple interactions |
ISO |
betulin affects the reaction [BRAF protein affects the susceptibility to [dabrafenib co-treated with trametinib]]; BRAF protein affects the reaction [[APS-2-79 results in increased susceptibility to trametinib] which results in increased phosphorylation of MAPK1 protein]; BRAF protein affects the reaction [[APS-2-79 results in increased susceptibility to trametinib] which results in increased phosphorylation of MAPK3 protein]; BRAF protein affects the susceptibility to [dabrafenib co-treated with trametinib]; fatostatin affects the reaction [BRAF protein affects the susceptibility to [dabrafenib co-treated with trametinib]]; trametinib affects the reaction [[BRAF protein affects the susceptibility to Vemurafenib] which affects the cleavage of SREBF1 protein]; trametinib affects the reaction [[BRAF protein affects the susceptibility to Vemurafenib] which affects the expression of ACACA mRNA]; trametinib affects the reaction [[BRAF protein affects the susceptibility to Vemurafenib] which affects the expression of ACLY mRNA]; trametinib affects the reaction [[BRAF protein affects the susceptibility to Vemurafenib] which affects the expression of FASN mRNA]; trametinib affects the reaction [[BRAF protein affects the susceptibility to Vemurafenib] which affects the phosphorylation of MAPK1 protein]; trametinib affects the reaction [[BRAF protein affects the susceptibility to Vemurafenib] which affects the phosphorylation of MAPK3 protein] |
CTD |
PMID:27556948 PMID:29950559 |
|
NCBI chr 4:68,375,484...68,510,652
Ensembl chr 4:68,384,649...68,510,463
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
ISO |
[GNAQ gene mutant form results in increased susceptibility to [trametinib co-treated with omipalisib]] which results in increased cleavage of CASP3 protein; trametinib promotes the reaction [physapubescin B results in increased expression of CASP3 protein modified form] |
CTD |
PMID:22733540 PMID:33035574 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp7 |
caspase 7 |
multiple interactions |
ISO |
[GNAQ gene mutant form results in increased susceptibility to [trametinib co-treated with omipalisib]] which results in increased cleavage of CASP7 protein |
CTD |
PMID:22733540 |
|
NCBI chr 1:255,437,195...255,476,737
Ensembl chr 1:255,437,172...255,476,729
|
|
G |
Casp9 |
caspase 9 |
multiple interactions |
ISO |
trametinib promotes the reaction [physapubescin B results in increased expression of CASP9 protein modified form] |
CTD |
PMID:33035574 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Ccl5 |
C-C motif chemokine ligand 5 |
multiple interactions |
ISO |
trametinib promotes the reaction [Lipopolysaccharides results in increased expression of CCL5 mRNA]; trametinib promotes the reaction [Poly I-C results in increased expression of CCL5 mRNA] |
CTD |
PMID:25780039 |
|
NCBI chr10:68,322,826...68,327,365
Ensembl chr10:68,322,829...68,327,377
|
|
G |
Cxcl10 |
C-X-C motif chemokine ligand 10 |
multiple interactions |
ISO |
trametinib promotes the reaction [Lipopolysaccharides results in increased expression of CXCL10 mRNA]; trametinib promotes the reaction [Poly I-C results in increased expression of CXCL10 mRNA] |
CTD |
PMID:25780039 |
|
NCBI chr14:15,704,772...15,706,969
Ensembl chr14:15,704,758...15,706,975
|
|
G |
Fasn |
fatty acid synthase |
multiple interactions |
ISO |
trametinib affects the reaction [[BRAF protein affects the susceptibility to Vemurafenib] which affects the expression of FASN mRNA] |
CTD |
PMID:29950559 |
|
NCBI chr10:106,072,093...106,090,259
Ensembl chr10:106,072,091...106,090,261
|
|
G |
Gna11 |
G protein subunit alpha 11 |
increases response to substance |
ISO |
GNA11 protein mutant form results in increased susceptibility to trametinib |
CTD |
PMID:22733540 |
|
NCBI chr 7:8,163,752...8,177,636
Ensembl chr 7:8,162,750...8,179,812
|
|
G |
Gnaq |
G protein subunit alpha q |
multiple interactions increases response to substance |
ISO |
[GNAQ gene mutant form results in increased susceptibility to [trametinib co-treated with omipalisib]] which results in increased cleavage of CASP3 protein; [GNAQ gene mutant form results in increased susceptibility to [trametinib co-treated with omipalisib]] which results in increased cleavage of CASP7 protein; GNAQ gene mutant form results in increased susceptibility to [trametinib co-treated with omipalisib] GNAQ protein mutant form results in increased susceptibility to trametinib |
CTD |
PMID:22733540 |
|
NCBI chr 1:213,425,631...213,671,947
Ensembl chr 1:213,424,465...213,667,672
|
|
G |
Ifnb1 |
interferon beta 1 |
multiple interactions |
ISO |
trametinib promotes the reaction [Lipopolysaccharides results in increased expression of IFNB1 mRNA]; trametinib promotes the reaction [Poly I-C results in increased expression of IFNB1 mRNA] |
CTD |
PMID:25780039 |
|
NCBI chr 5:103,020,969...103,021,523
Ensembl chr 5:103,020,969...103,021,523
|
|
G |
Irf3 |
interferon regulatory factor 3 |
multiple interactions |
ISO |
trametinib promotes the reaction [Lipopolysaccharides results in increased phosphorylation of IRF3 protein] |
CTD |
PMID:25780039 |
|
NCBI chr 1:95,479,966...95,484,926
Ensembl chr 1:95,479,821...95,484,935
|
|
G |
Jun |
Jun proto-oncogene, AP-1 transcription factor subunit |
multiple interactions |
ISO |
[omipalisib co-treated with trametinib] results in increased phosphorylation of JUN protein; JUN results in decreased susceptibility to [omipalisib co-treated with trametinib] |
CTD |
PMID:22733540 |
|
NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656
|
|
G |
Map1lc3b |
microtubule-associated protein 1 light chain 3 beta |
multiple interactions |
ISO |
trametinib affects the expression of and affects the lipidation of MAP1LC3B protein |
CTD |
PMID:30339727 |
|
NCBI chr19:49,665,795...49,673,655
Ensembl chr19:49,665,791...49,677,690
|
|
G |
Map2k1 |
mitogen activated protein kinase kinase 1 |
decreases response to substance multiple interactions |
ISO |
MAP2K1 protein mutant form results in decreased susceptibility to trametinib [MAP2K1 protein mutant form results in decreased susceptibility to trametinib] inhibits the reaction [trametinib results in decreased phosphorylation of MAPK1 protein]; [MAP2K1 protein mutant form results in decreased susceptibility to trametinib] inhibits the reaction [trametinib results in decreased phosphorylation of MAPK3 protein] |
CTD |
PMID:29768711 |
|
NCBI chr 8:64,683,449...64,754,900
Ensembl chr 8:64,683,449...64,755,147
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions decreases phosphorylation |
ISO |
[APS-2-79 results in increased susceptibility to trametinib] which results in increased phosphorylation of MAPK1 protein; [MAP2K1 protein mutant form results in decreased susceptibility to trametinib] inhibits the reaction [trametinib results in decreased phosphorylation of MAPK1 protein]; [omipalisib co-treated with trametinib] results in decreased phosphorylation of MAPK1 protein; BRAF protein affects the reaction [[APS-2-79 results in increased susceptibility to trametinib] which results in increased phosphorylation of MAPK1 protein]; trametinib affects the reaction [[BRAF protein affects the susceptibility to Vemurafenib] which affects the phosphorylation of MAPK1 protein]; trametinib inhibits the reaction [physapubescin B results in increased phosphorylation of MAPK1 protein] trametinib inhibits the reaction [camostat results in increased phosphorylation of MAPK1 protein]; trametinib inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of MAPK1 protein]; trametinib inhibits the reaction [Poly I-C results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:22733540 PMID:25104499 PMID:25780039 PMID:27556948 PMID:29768711 PMID:29950559 PMID:33035574 More...
|
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions decreases phosphorylation |
ISO |
[APS-2-79 results in increased susceptibility to trametinib] which results in increased phosphorylation of MAPK3 protein; [MAP2K1 protein mutant form results in decreased susceptibility to trametinib] inhibits the reaction [trametinib results in decreased phosphorylation of MAPK3 protein]; [omipalisib co-treated with trametinib] results in decreased phosphorylation of MAPK3 protein; BRAF protein affects the reaction [[APS-2-79 results in increased susceptibility to trametinib] which results in increased phosphorylation of MAPK3 protein]; trametinib affects the reaction [[BRAF protein affects the susceptibility to Vemurafenib] which affects the phosphorylation of MAPK3 protein]; trametinib inhibits the reaction [physapubescin B results in increased phosphorylation of MAPK3 protein] trametinib inhibits the reaction [camostat results in increased phosphorylation of MAPK3 protein]; trametinib inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of MAPK3 protein]; trametinib inhibits the reaction [Poly I-C results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:22733540 PMID:25104499 PMID:25780039 PMID:27556948 PMID:29768711 PMID:29950559 PMID:33035574 More...
|
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Myc |
MYC proto-oncogene, bHLH transcription factor |
decreases expression |
ISO |
trametinib results in decreased expression of MYC protein |
CTD |
PMID:22733540 |
|
NCBI chr 7:93,593,705...93,598,633
Ensembl chr 7:93,593,705...93,598,630
|
|
G |
Ngfr |
nerve growth factor receptor |
increases expression affects response to substance |
ISO |
trametinib results in increased expression of NGFR protein NGFR protein affects the susceptibility to trametinib |
CTD |
PMID:30339727 |
|
NCBI chr10:80,515,287...80,533,518
Ensembl chr10:80,515,299...80,533,518
|
|
G |
Rb1 |
RB transcriptional corepressor 1 |
decreases phosphorylation |
ISO |
trametinib results in decreased phosphorylation of RB1 protein |
CTD |
PMID:22733540 |
|
NCBI chr15:48,371,295...48,502,473
Ensembl chr15:48,371,296...48,502,302
|
|
G |
Rps6kb1 |
ribosomal protein S6 kinase B1 |
decreases phosphorylation |
ISO |
trametinib results in decreased phosphorylation of RPS6KB1 protein |
CTD |
PMID:22733540 |
|
NCBI chr10:71,323,777...71,367,908
Ensembl chr10:71,323,777...71,367,908
|
|
G |
Sqstm1 |
sequestosome 1 |
decreases expression |
ISO |
trametinib results in decreased expression of SQSTM1 protein |
CTD |
PMID:30339727 |
|
NCBI chr10:34,525,517...34,536,685
Ensembl chr10:34,525,519...34,536,673
|
|
G |
Srebf1 |
sterol regulatory element binding transcription factor 1 |
multiple interactions |
ISO |
trametinib affects the reaction [[BRAF protein affects the susceptibility to Vemurafenib] which affects the cleavage of SREBF1 protein] |
CTD |
PMID:29950559 |
|
NCBI chr10:45,007,637...45,029,650
Ensembl chr10:45,007,637...45,029,650
|
|
G |
Stat3 |
signal transducer and activator of transcription 3 |
increases phosphorylation multiple interactions |
ISO |
trametinib results in increased phosphorylation of STAT3 protein physapubescin B inhibits the reaction [trametinib results in increased phosphorylation of STAT3 protein] |
CTD |
PMID:33035574 |
|
NCBI chr10:85,811,206...85,863,057
Ensembl chr10:85,811,218...85,863,057
|
|